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Chronic lung disease determines the morbidity and mortality of cystic ﬁbrosis (CF) patients. The pulmonary immune response in CF is
characterized by an early and non-resolving activation of the innate immune system, which is dysregulated at several levels. Here we provide a
comprehensive overview of innate immunity in CF lung disease, involving (i) epithelial dysfunction, (ii) pathogen sensing, (iii) leukocyte
recruitment, (iv) phagocyte impairment, (v) mechanisms linking innate and adaptive immunity and (iv) the potential clinical relevance. Dissecting
the complex network of innate immune regulation and associated pro-inﬂammatory cascades in CF lung disease may pave the way for novel
immune-targeted therapies in CF and other chronic infective lung diseases.
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inﬂammation in CF
Mutations in the cystic fibrosis transmembrane conductance
regulator (CFTR) gene cause a critical impairment of innate host
defense systems in the lungs of cystic fibrosis (CF) patients. This
results in an early and severe form of chronic airway disease,
featuring mucus obstruction, neutrophil-dominated airway in-
flammation and bacterial infection, finally leading to progressive
pulmonary damage with bronchiectasis and emphysema [1–4].
The airways are lined by an epithelial layer that integrates
several functions important for effective defense against
inhaled pathogens and other noxious agents, ranging from a
barrier function, proper surface hydration by regulated transport
of ions and fluid, mucus secretion, and mucociliary clearance
[5,6] to expression of antimicrobial peptides [7], receptors that
recognize pathogen associated molecular patterns (PAMPs) and
host-derived danger signals (DAMPs) and the secretion of
chemokines and cytokines that orchestrate the recruitment of
leucocytes [8] as well as the local immune responses in the
airway lumen [9]. Given this broad functionality of the airway
epithelium in innate lung defense, and the fact that the CFTR
protein is expressed in the apical membrane of the surface
epithelium and in submucosal glands [10,11], the link between
epithelial CFTR dysfunction and the pathogenesis of CF airway
disease has long been in the focus of CF research.
In healthy airways, CFTR acts as a cAMP-dependent Cl−
channel [12,13] that works in concert with the Ca2+-activated
Cl− channel (CaCC) [14] to secrete Cl− and fluid required for
hydration of mucins and other secreted molecules that form
airway mucus. In the surface epithelium, CFTR also functions
as regulator of the amiloride-sensitive epithelial Na+ channel
(ENaC) that constitutes the limiting pathway for Na+ and fluid
absorption [15]. Given this dual functionality in vectorial ion
transport, CFTR plays a key role in coordinate regulation of
secretion and absorption of NaCl and fluid, and hence airway
surface liquid (ASL) homeostasis [6,16]. Accordingly, in CF
airways, epithelial CFTR dysfunction results in an imbalance
between Cl− secretion and ENaC-mediated Na+ absorption
rendering the airway surfaces vulnerable to ASL volume
depletion. In a series of studies using highly-differentiated
primary airway cultures it was shown that airway surface
dehydration impaired ciliary beating and mucus transport, and
promoted mucus stasis and adhesion in CF airway epithelia
[17,18]. Since mucociliary clearance acts as an important
integral part of the innate pulmonary defense system, these
results indicated that mucociliary dysfunction due to airway
surface dehydration constitutes a disease-causing mechanism
that links the basic CF defect to impaired airway defense and
CF lung disease. The in vivo evaluation of the “dehydration
hypothesis” was hampered for a long time by the fact thatCftr-deficient mice did neither show abnormal Cl− or Na+
transport in their lower airways, nor develop CF-like lung
disease [19–23]. This limitation was overcome in a mouse
model with airway-specific overexpression of the β subunit of
ENaC (βENaC) developed to mimic increased Na+ absorption
characteristic of CF airways [19,24]. In this model, an
imbalance between Cl− secretion and Na+ absorption caused
ASL depletion and reduced mucus clearance in vivo, and
resulted in a lung disease that shares many features of early
lung disease in CF patients, including airway mucus obstruc-
tion, reduced bacterial clearance, chronic neutrophilic inflam-
mation and emphysema, supporting the notion that epithelial
impairment initiates and sustains inflammation [19,24,25].
Further, studies in βENaC-overexpressing mice demonstrated
that preventive pharmacological targeting of ASL depletion by
the ENaC inhibitor amiloride has substantial therapeutic effects
on CF-like mucus obstruction and airway inflammation [26].
These results validated impaired ASL homeostasis resulting from
a basic epithelial ion transport defect in CF airways as a
disease-initiating mechanism in the in vivo pathogenesis and as a
therapeutic target of CF lung disease. Hence, the βENaC-
overexpressing mouse will also provide opportunities for further
in vivo elucidation of the molecular mechanisms underlying the
initiation and perpetuation of dehydration-induced airway
inflammation, and its contribution to impaired host defense and
lung damage that will be reviewed in the sections below.
In addition to the well established impairment of epithelial
ion transport, other epithelial dysfunctions have been implicat-
ed in chronic inflammation and infection of CF airways,
including increased apoptosis due to accumulation of ceramide,
a promising approach for drug targeting [27,28], intrinsic
pro-inflammatory properties, exaggerated inflammatory re-
sponses to viral and bacterial infections, and reduced clearance
of Pseudomonas aeruginosa (P. aeruginosa) [29–33]. For
studies indicating a link between CFTR and glutathione or
Ca2+ channels we refer to a recent review by Ratner et al. [34].
We expect that the recent development of small-molecule
CFTR modulators designed to improve impaired CFTR Cl−
channel function in CF [35,36], together with sensitive assays
for quantitative assessment of mutant CFTR function in native
tissues [37,38], will help to dissect the relative roles of the CF
ion transport defect and other epithelial dysfunctions in chronic
inflammation and impaired host defense in the CF lung.
2. CF pathogens are sensed through distinct pattern
recognition receptors
Infections with Staphylococcus aureus (S. aureus),
Haemophilus influenzae (H. influenzae) and P. aeruginosa
are mainly characteristic for CF patients. Other emerging
bacterial pathogens, such as Burkholderia cepacia and
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fumigatus [39], Candida albicans [40] or Scedosporium
apiospermum [41] are increasingly appreciated to play a role in
CF lung disease [3,42]. Whereas S. aureus and H. influenzae
infections manifest in younger CF patients, P. aeruginosa is the
predominant pathogen in later infancy, teenage-age and adult CF
patients. Colonization with Aspergillus and/or Candida spp. is
mainly found in older CF patients, but their pathophysiological
relevance is poorly understood so far [39,43,44]. Infections with
P. aeruginosa seem to favor colonization with A. fumigatus and
associated allergic bronchopulmonary aspergillosis (ABPA)
[39,43], potentially due to a P. aeruginosa-mediated Th2 shift
[45].
Given the long-term and intimate contact of pathogens with
the lining CF airways, the mechanisms by which these pathogens
are recognized by the host are of key relevance for the
understanding of innate immunity in CF lung disease. In general,
the innate immune system senses conserved molecular patterns
using pattern recognition receptors (PRR), with Toll-like re-
ceptors (TLRs) representing the prototypic PRRs [46,47]. Other
non-TLR PRRs include complement receptors, Fc receptors,
nucleotide-binding oligomerization domain family (NOD)-like
receptors, scavenger receptors, RIG-like helicases, nucleic acid
receptors and others [48]. The majority of TLRs recognize
bacterial patterns (TLR1, TLR2, TLR4, TLR5, TLR6 and TLR9,
TLR10, TLR11) with TLR4 sensing lipopolysaccharide (LPS),
TLR5 flagellin, TLR9 CpG oligonucleotides and TLR11 uro-
pathogenic bacteria and/or profilin from protozoa. Viral PAMPs
are recognized through TLR3 (double-stranded RNA, dsRNA),
TLR7 and TLR8 (single-stranded RNA, ssRNA). Beyond
microbial PAMPs (recently also termed for microbes in general
independent of their pathogenicity as microbe-associated molecu-
lar pattern, MAMPs), TLRs sense endogenous ligands (DAMPs),
including heat shock protein 70 (HSP-70), proinflammatory extra
domain A of fibrinogen, extracellular CXCR1 moieties, heparan
sulfate fragments, elastase, hyaluronic acid fragments (TLR4) and
others. TLRs are expressed by a variety of immune and structural
cells, including monocytes/macrophages, dendritic cells, lympho-
cytes, endothelial cells, myocytes, epithelial cells, neutrophils and
others. Here we will focus on TLRs expressed by epithelial cells,
since they represent the first cellular line of pattern recognition in
the CF airway microenvironment.
Airway epithelial cells including tracheal, bronchial and
alveolar type II cells express a broad repertoire of TLRs
[9,49–52]. Most anti-bacterial TLRs are appropriately exposed
on the mucosal surface of the airway and can be readily
activated by superficial exposure to microbial factors. The
predominant TLR expressed on the surface of bronchial
epithelial cells in vivo appears to be TLR2, with other TLRs
(TLR3, TLR4, TLR5) residing mainly intracellularly yet dis-
playing low level surface expression. While in macrophages
and dendritic cells [53] TLR7, TLR8 and TLR9 reside in
endosomes, in both immortalized and differentiated primary
airway epithelial cells [54,55], TLR9 has also been detected on
the cell surface expression using flow cytometry. Some TLRs
can be mobilized to the airway epithelial cell surface following
stimulation with microbial factors. For example cell surfacelocalization of TLR4 and TLR5 is promoted by Respiratory
Syncytial Virus (RSV) infection and flagellin, respectively
[56,57], whereas infection with P. aeruginosa enhances TLR2
localization within lipid rafts on the apical surface of airway
epithelial cells [58].
Three early reports described TLR expression in primary and
transformed CF airway epithelial cells [55,59,60]. These studies
provided the first evidence that TLRs 1–10, the TLR4 accessory
proteinMD2 and the TLR adaptor protein myeloid differentiation
primary response gene 88 (MyD88) are expressed and functional
in CF airway epithelium. As in non-CF airway epithelial cells,
bacterial stimulation of CF cells caused upregulation of TLR2,
albeit reduced. Similarly, TLR4 is displayed poorly on the apical
surface in CF cells and fails to respond well to stimulation with
LPS. John et al. investigated the functional consequences of this,
and independently confirmed that TLR4 expression is decreased
in CF bronchial epithelium resulting in weaker than normal
MyD88 and TRIF-dependent signaling [61,62], possibly leading
to impaired adaptive immune responses. For further detailed
discussion of the role of TLRs in CF airway epithelial cell
responses we also refer to a recently published review [63].
TLR5 is a key TLR expressed by airway epithelial cells and
can mediate inflammatory responses to flagellin-expressing but
not fliC (flagellin-deficient) mutants of P. aeruginosa and B.
cepacia [64]; it represents also the predominant TLR responsible
for lung epithelial inflammatory responses to B. cenocepacia
[65]. In CF airway epithelial cells inhibition of TLR5 can abolish
IL-6 production normally generated following exposure to P.
aeruginosa, identifying TLR5 as a potential therapeutic target for
CF lung inflammation [66]. Interestingly CF adults with a TLR5
1174CNT SNP, which encodes a premature stop codon in TLR5
that is associated with decreased flagellin-responsiveness, appear
to have improved nutritional status as measured by higher body
mass index [67]. Thus TLR5 could also represent a modifier gene
for CF. However antagonism of TLR5 alone may not be
sufficient to decrease CF airway epithelial cell responses to P.
aeruginosa. Reduced glutathione levels sensitize these cells to
the action of reactive oxygen species generated by NADPH
oxidase leading to enhanced CXCL8/IL-8 expression [68].
Therefore, targeting both oxidants and TLRs, in addition to
other recently reported experimental anti-inflammatory strate-
gies, is likely to have greater therapeutic benefit. CF patients are
commonly co-colonized with Aspergillus species [69]. Conidial
dsRNA can induce interferon-β via activation of TLRs in non-CF
airway epithelial cells [70], however it remains to be shown
whether CF airway epithelial cells respond in a similar way or
whether their response to Aspergillus occurs as a result of
chitin-induced activation of TLR2 as seen in murine macro-
phages [71].
The CF lung is a MAMP/PAMP- and DAMP-rich milieu
and, in addition to classical TLR agonists, contains a selection
of factors that can indirectly activate TLRs. Neutrophil elastase
activates TLR4 via a mechanism involving meprin and/or
Tumor necrosis factor-alpha-converting enzyme/a disintegrin
and metalloproteinase domain 17 (TACE/ADAM17), TGF‐α
and EGFR [72–75], leading to exaggerated IL-8/CXCL8 and
mucin gene expression while hemoglobin, which can be present
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as a result of cleavage by elastase and/or P. aeruginosa-derived
proteases that can similarly activate TLR signaling and
proinflammatory gene expression via EGFR-TLR signaling
[76]. Although TLR hyper-responsiveness is largely accepted to
contribute to CF lung pathology there are a number of contexts
where inadequate bronchial epithelial TLR‐mediated responses
can occur and are likely to impact negatively on pulmonary
inflammation. In CF females high circulating estrogen levels can
impair TLR-induced NFκB activation and cytokine expression via
estrogen-receptor-β-mediated upregulation of secretory leucopro-
tease inhibitor (SLPI) [77]: SLPI is an antiprotease with
anti-inflammatory and immunomodulatory properties that can
prevent NFκB activation by interfering with proteasomal degrada-
tion of IκB [78,79] and by blocking p65 binding to NFκB
consensus sequences in chromosomal DNA [80]. This, along with
other estrogen-induced effects, likely contributes to the gender gap
in CF whereby CF females have poorer lung function, worse
exacerbations and convert to mucoid strains of P. aeruginosa
prematurely compared to males. Altered microRNA expression in
CF bronchial epithelium in vivo can also impact on TLR signaling
potentially leading to TLR hypo-responsiveness [81]. Decreased
miR-126 controls reciprocal increases in TOM1 which can
interfere with TLR2 and TLR4 responses and may also contribute
to CF-specific decreased cell surface expression of TLR4. These
subtle regulatory mechanisms underscore the importance of
carefully considering the context and timing in which future
TLR-directed therapies should be prescribed.
3. Chemokines and extracellular matrix break-down products
orchestrate the recruitment of leukocytes into CF airways
As a consequence of epithelial dysfunction and pathogen
sensing, a pro-inflammatory cascade is initiated in CF airways
that leads to the recruitment of leukocytes from the bone-marrow
niche via the circulation into the airways. While professional
phagocytes, such as macrophages and microphages (neutrophils),
are essential in clearing the lungs from bacterial and fungal
pathogens, their uncontrolled action in the absence of microbial
threat causes tissue damage and tissue remodeling. Therefore,
the in-depth understanding of mechanisms driving leukocyte
migration into CF airways under infectious and non-infectious
conditions is pivotal for future therapeutic approaches targeting
specific, host-damaging recruitment pathways, while preserving
antimicrobial host defense capacities.
Our current view of leukocyte migration in chronic neutrophilic
inflammation becomes increasingly complex and has overcome
the traditional concept that single disease-associated chemo-
attractants direct leukocyte migration into tissues. Leukocyte
transmigration into the extravascular space represents a multi-step
process, involving rolling, activation, adhesion and diapedesis,
requiring the concerted action of integrins, selectins and
chemokines [82–84]. There is limited evidence for CF-associated
dysregulations in the context of neutrophil transmigration. The
relevant pathomechanisms seem to be complex, since CFTR
neutrophil-intrinsic, airway epithelial cell-dependent and transmi-
gratory lung epithelium feed-back factors have to be considered[85–87]. Related to transmigration mechanisms, dysregulations in
L-selectin shedding [88], complement receptor (CD11b/CD18)
expression [89] and ICAM-dependent airway epithelial cell–
neutrophil interactions [90] have been described.
Tissue-released chemokines (major source: epithelial cells and
macrophages) attract leukocytes via chemokine gradients to the site
of inflammation, putting chemokines and their G-protein coupled
receptors in the spotlight of targeted anti-inflammatory strategies
[91]. However, the previous years have substantially extended the
notion that chemokines are predominantly responsible for
attracting leukocytes to diseased organs by demonstrating that
products liberated from necrotic cells (alarmins) and tissue
extracellular matrix break-down products, as discussed below in
detail, are capable of initiating and sustaining leukocyte recruit-
ment [92,93].
3.1. Cytokines and chemokines
Cytokines, as small molecular weight proteins, influence a
plethora of biological processes including cellular activation,
recruitment, cell death, and repair and play a critical role in the
regulation of innate immunity in a variety of disorders including
CF [94]. Due to the chronic bacterial colonization of the CF
airways, cytokines are continuously produced at the pulmonary site
of inflammation and exert their influence in a paracrine manner at
the interface of bacteria and airway epithelial cells [95]. This
ongoing activation of innate immune receptors by bacteria and
bacteria-associated PAMPs/MAMPs leads in the CF microenvi-
ronment to the dysregulated production of cytokines; elevated
levels of pro-inflammatory cytokines (such as TNF-α, IL-6, IL-1β)
and reduced levels of anti-inflammatory cytokines (such as IL-10)
have been reported in the bronchoalveolar lavage (BAL) and
sputum of patients with CF lung disease [96]. Despite general
agreement about the imbalance of these cytokines in the CF lung, it
remains a challenge to assess how these cytokines regulate
biological and cellular functionalities in the CF lung.
The prototypic pro-inflammatory cytokine TNF-α is mainly
released from monocytes and macrophages and has pleiotropic
effects central to innate immunity, including inflammatory cell
recruitment and induction of additional cytokines [97]. TNF-α
has been traditionally regarded as an early release cytokine and,
therefore, its persistence in the CF airways strongly suggests
ongoing production from both resident alveolar macrophages
and recruited monocytes [98]. Although TNF-α is elevated in
the CF lung, it has not shown a strong correlation with
progression of disease [99,100]. In addition, there have been
variable results in the regulation of TNF-α production during
pulmonary exacerbation of CF lung disease [101,102]. Besides
TNF-α, IL-1 (both IL-1α and IL-1β) have been studied in the
context of CF. Similar to TNF-α, IL-1β is released from
macrophages/monocytes and is actively involved in inflamma-
tory cell recruitment and the amplification of the pro-
inflammatory cytokine response [103]. Both isoforms have
been found to be elevated in the blood and airway samples (BAL
and sputum) from CF patients [100,104–106]. IL-1β levels have
been shown to be increased both in the sputum and BAL of CF
patients who were chronically colonized with P. aeruginosa
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parallel, eradication of P. aeruginosa leads to decreased IL-1β
levels in the BAL of CF children [108]. Despite these findings, the
correlation of IL-1β with progression of disease remains poorly
linked. IL-10 is a critical anti-inflammatory protein capable of
reducing the production of multiple pro-inflammatory proteins.
The levels of IL-10 have been found to be decreased in the CF lung
of older patients [107]; this may in part be due to differences in
secretion of IL-10 from airway epithelial cells [109]. Interestingly,
younger children do not seem to exhibit differences in IL-10 levels
between CF and non-CF individuals [110]. Due to potential
differences observed of IL-10 in older patients, there is significant
interest in directed gene therapy to restore IL-10 balance in CF lung
disease and preclinical studies are underway [111]. The potential
role of these CF-associated cytokines as disease biomarkers is
reviewed in detail elsewhere [112]. Therapeutically, anti-cytokine
strategies (biologicals), which are already successfully implement-
ed in the therapy of rheumatoid arthritis, are reasonable to consider
in progressive CF lung disease. However, the increased infection
susceptibility and related side effects [113] have to be taken into
account, in particular in older CF patients suffering from chronic
bacterial infections.
Chemotactic cytokines, termed chemokines, orchestrate the
recruitment and activation of inflammatory cells [114,115].
Perhaps the best studied chemokine in CF lung disease is
CXCL8 (IL-8). CXCL8 acts on both CXCR1 (IL-8RA, CD181)
and CXCR2 (IL-8RB, CD182) surface receptors; this chemokine
exhibits pleotropic effects on neutrophils, acting as a potent
chemoattractant and inducing degranulation and superoxide
production [116]. Many groups have reported elevated levels
of this chemokine in the BAL and sputum of both CF adults and
children [107,112,117–119]. Further cellular studies demonstrated
that CXCR1, but not CXCR2, is involved in antibacterial effector
functionalities by neutrophils and that CXCR1 is proteolytically
cleaved in CF airways, thereby disabling CXCL8-mediated
enhancement of anti-bacterial effector functions [117]. There are
also reports of CXCL8 levels correlating with patients' clinical
status, including Schwachmann scores, bacterial colonization with
P. aeruginosa, and lung function [120–122]. Despite these
findings, studies targeting this molecule in chronic obstructive
pulmonary disease (COPD), featuring a similar chronic neutro-
philic lung disease, have not shown clinical benefits so far [123],
strongly suggesting additional, redundant chemotactic and activa-
tion pathways being important in COPD and probably CF disease
pathogenesis. Other chemokines that have been studied in CF
include CCL2 [124], CCL3, CCL4, and CCL20 [125] as well as a
deficiency of the Th1- and human immunodeficiency virus
(HIV)-associated chemokine CCL5 (RANTES) [126,127]. In
ABPA, the Th2-associated CC chemokines CCL17 and CCL22
have been proposed as potential biomarkers [43,128–132].
3.2. Proline–glycine–proline and high mobility group box
protein-1
Beyond the canonical pathways of preformed cytokines/
chemokines regulating inflammatory response in CF, recent
evidence suggests a significant noncanonical pathway responsibleof neutrophil influx. This pathway involves the coordinated
cleavage of extracellular matrix (ECM) to small fragments, capable
of acting on chemokine receptors on inflammatory cells. Although
hypothesized in human disease for over 50 years, the identification
of these fragments and mechanisms related to their action was
poorly understood for a long time [133]. Recently, however, a
fragment of collagen proline–glycine–proline (PGP) has been
identified in the sputum and serum of CF patients [134]. This
peptide acts as a ligand mimetic for CXCR1 and CXCR2 due to
similarities in the structure of ELR+ CXC chemokines. PGP (and
its N-terminal acetylated form, Ac-PGP) have been shown to
induce chemotaxis, produce superoxide, and induce release of
proteases from neutrophils [135]. The liberation of PGP from
collagen is a multiprotease pathway, with the initial cleavage of
collagen mediated by matrix metalloprotease (MMP)-8 and
MMP-9 and subsequent cleavage conducted by prolyl endopep-
tidase (PE), a serine protease first described in this work as playing
a role in pulmonary inflammation [136]. Recently, a pathway
regulating PGP degradation and inactivation has been described
through a novel aminopeptidase activity of the enzyme
leukotrieneA4 hydrolase (LTA4H) [137]. Persistence of PGP in
chronic neutrophilic lung disorders has been well-documented and
PGP peptides were found to be elevated in the sputum of
individuals with CF lung disease compared to non-lung disease
controls [136]. At the beginning of inpatient exacerbation, PGP
peptides were increased and these peptides decreased at the end of
therapy, consistent with improvement in lung function. However,
the end-of-exacerbation PGP levels were still significantly higher
than non-lung disease controls, suggesting ongoing inflammatory
response in the lung despite resolution of exacerbation. PGP
peptides have also been detected in the serum of CF patients,
suggesting a possible systemic role for this peptide in human
disease; ongoing research is focusing on the variety of systemic
effects of this peptide in CF disease. Fig. 1 illustrates the proposed
mechanisms by which PGP drives and perpetuates chronic
neutrophilic airway inflammation in CF.
A further host-derived inflammatory protein involved in CF
lung is high mobility group box protein-1 (HMGB1). This
chromatin protein is released from inflammatory cells (such as
monocytes) or from necrotic cells [138] and acts intracellularly to
enhance nucleoprotein interactions [139]. Once released,
this protein can act as a potent proinflammatory cytokine by its
binding to RAGE, TLR and CXCR4 receptors [140,141].
Recently, Rowe et al. have described the increased presence of
extracellular HMGB1 levels in the secretions of CF patients and in
the βENaC mouse model [134]. In addition, this elevation of
HMGB1 closely correlated with the presence of the chemotactic
collagen fragment PGP and offers the consideration if these
pathways of inflammation are linked [142].
4. Recruited phagocytes are impaired in the
CF microenvironment
Bone marrow-derived immune cells are continuously recruited
to the infective pulmonarymicroenvironment in CF lung disease in
order to clear the bronchoalveolar pathogens. Neutrophils and
macrophages which are the major antibacterial effector cells, are
Fig. 1. Mechanisms initiating neutrophil influx into the CF lung. Panel A represents the healthy airway; Panel B represents the CF airway. Airway surface liquid
(ASL, mucus layer) is reduced in the CF airway, leading to viscous mucus with decreased mucociliary transport and bacterial colonization. In response to bacteria
(red), epithelial cells in CF patients release high amounts of IL-8/CXCL8, resulting in neutrophil influx. Degranulation of activated immigrated neutrophils releases
various proteases (blue), such as elastase, MMP-2, MMP-8, MMP-9 and prolyl endopeptidase (PE). The coordinated action of MMP-8, MMP-9 and PE triggers the
cleavage of extracellular matrix (ECM), such as collagen, to small fragments, importantly Proline–Glycine–Proline (PGP, green circle). In healthy individuals, the
enzyme leukotrieneA4 hydrolase (LTA4H) (light blue triangles) is able to degrade PGP, while unopposed proteolytic cascades in CF patients lead to PGP generation,
triggering neutrophil influx and thereby perpetuating inflammation.
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here in detail, while dendritic cells (DCs) phagocytose but act
mainly as antigen presentators and T cell instructors to bridge
innate and adaptive immunity and are only summarized briefly at
the end of this paragraph, particularly regarding the paucity of data
concerning DCs in CF.
4.1. Neutrophils
In healthy adults, 11 neutrophils daily transit through the
circulation [143]. Upon infection, these neutrophils rapidly
transmigrate to the site of inflammation, where they sense
PAMPs and/or DAMPs and combat pathogens. Airway fluids
(sputum, BALF) of CF patients contain millions of neutrophils,
which led to the well-established notion that CF lung disease is
dominated by a neutrophilic airway inflammation [8,117]. Ingeneral, the pathophysiological role of airway neutrophils in
CF and other chronic neutrophilic lung diseases is two-faced:
On the one hand they are required for antibacterial and
antifungal host defense, on the other hand they can cause
significant parenchymal lung tissue damage when they ac-
cumulate over longer time periods and liberate their toxic
granule contents, mainly serine and metalloproteases as well as
oxidants, in an uncontrolled fashion [144]. Based on this
scenario, the targeting of distinct harmful subtypes of airway
neutrophils, while preserving other beneficial subtypes, may
provide the possibility to specifically modulate the neutrophilic
activity in CF lung diseases.
Regarding the role of CFTR in neutrophil homeostasis and
function, studies suggest a functional relevance of CFTR in
regulating anti-bacterial neutrophil activities (discussed in
detail below) [145–147]. Isolated neutrophils from CF patients
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control cells [148] and showed enhanced migratory capacities
[149], but a blunted phagocytic capacity [150]. On the other
hand, studies indicated that neutrophils from CF patients
showed no difference in terms of phagocytosis (in newborns)
[151] or ROS generation [152], suggesting that local/pulmo-
nary factors also play a role in modulating neutrophil effector
functionalities in vivo. This notion is supported by the finding
that CF sputum stimulates CD18-independent neutrophil mi-
gration across endothelial cells [153]. Studies analyzing cell
death pathways in peripheral blood-isolated cells added another
angle by demonstrating that circulating neutrophils from CF
patients feature a slower apoptosis rate [154,155] [156,157].
When viewing these studies in combination, both systemic/
CFTR-associated, cell death-related as well as pulmonary
factors probably contribute in the regulation of neutrophil
functionality in CF airways.
Regarding the usefulness of neutrophils or neutrophil-
derived proteins, a large number of studies investigated the
relationship between neutrophil numbers, phenotypes and
neutrophilic mediators in CF patients and correlated them
with disease outcome parameters, such as pulmonary function
[32,45,112,118,130,131,158–165]. These studies provided ev-
idence that both the extent of neutrophilic airway inflammation
as well as neutrophil proteins, prototypically neutrophil elas-
tase, correlate with pulmonary obstruction (FEV1) in different
CF patient cohorts. A large US multicenter study compared
different CF sputum markers as predictors for FEV1 decline
and found that neutrophil elastase showed the highest cor-
relation with longitudinal FEV1 [118], suggesting sputum
elastase as a promising biomarker for CF airway inflammation.
Other studies analyzing BALF found increased elastolytic
activity in a subset of CF infants very early in the course of CF
lung disease [1], supporting, in line with murine βENaC studies
[19,24], the notion that neutrophilic–proteolytic inflammation
starts early in the pathogenesis of CF lung disease. Beyond
elastase, other studies found evidence for neutrophil-derived
proteins as potential biomarkers in CF lung disease, in par-
ticular calprotectin [166,167], a S-100 protein located in
specific granules, MMP‐9 [158,159,168] stored in tertiary
granules, myeloperoxidase (MPO) [169] and proteinase 3
[170,171] stored in primary granules, the chitinase-like protein
YKL-40 [160] and others. In a study comparing gene ex-
pression in peripheral blood neutrophils from CF patients and
healthy controls, 1050 genes were found to be upregulated
[172], with the majority not being studied so far in the context
of CF lung disease, indicating that the field of neutrophilic
inflammation in CF is complex and requires future studies to
gain mechanistic insights.
Neutrophils release their granules sequentially, starting with
secretory vesicles that shuttle between cytoplasmic compart-
ments and the plasma membrane, which are pivotal for
recycling and mobilization of complement-, Fc- and other
receptors. Tertiary granules contain MMP-9, a marker protein
involved in transmigration of neutrophils and the initiation of
proteolytic extracellular matrix degradation. Upon intensified
and prolonged stimulation, neutrophils liberate their secondarygranules that contain anti-microbial proteins, such as lactoferrin
and cathelicidine, liberated to cope with encountering patho-
gens. Upon direct pathogen contact, neutrophils engage their
strongest granule weapon, the primary or azurophilic granules.
This event liberates MPO and serine proteases that target both
engulfed pathogens in the phagolysosome or, when liberated in
an uncontrolled or pathogen-independent fashion, extracellular
matrix and leukocyte surface receptors, such as the CXCL8/
IL-8 receptor CXCR1 (CD181), T cell or complement re-
ceptors. These proteolytic effects are dependent on the
protease/anti-protease balance in the CF airway microenviron-
ment, a complex topic by itself [173,174]. Of note, ASL
without proteolytic activity has been shown to have no major
effect on neutrophil activity in vitro [175]. Given the stepwise
granule release mechanism, granule proteins detectable in CF
airway fluids may represent distinct stages of neutrophil
activation. For a more in-depth review on neutrophil granules
we refer to Hager et al. [176]. Consequently, studies in-
vestigating proteins characteristic for all four intracellular
neutrophil granule/vesicle compartments in peripheral and
airway neutrophils from CF patients and controls are warranted
to understand the differential activation state of CF neutrophils
comprehensively. Furthermore, longitudinal studies analyzing
neutrophil markers in CF airway fluids are required to
understand the kinetics of neutrophilic activation in CF lung
disease.
Beyond these studies, desmosin, a urinary marker of elastin
was found to be associated with disease outcome and inflamma-
tion in CF patients [29,177]. Recently, the neutrophil-derived
alpha-1 antitrypsin and CD16 protein heterocomplex (AAT:
CD16) has been reported as a potential biomarker for exacerba-
tions in CF [178]. Intriguingly, Voglis et al. showed that human
neutrophil peptides impaired the phagocytic capacity of neutro-
phils in an auto- and/or paracrine manner in both CF and non-CF
bronchiectatic conditions [179].
In the airway microenvironment of chronic P. aeruginosa
infections, infiltrated neutrophils are faced withQuorum sensing-
induced bacterial biofilms [180] and this interaction substantially
modulates the phagocyte's behavior. P. aeruginosa can exploit
the neutrophil-derived host DNA to form biofilms [181]. In turn,
CF airway fluid biofilm-associated neutrophils have been
described to be distinct in terms of impaired migration with
preserved phagocytosis [182], modulated respiratory burst
activity [183] and ongoing oxygen consumption [184]. Further
interaction mechanisms between P. aeruginosa and neutrophils
implicate TLRs, with TLR5 seeming to play a major role [185],
pyocyanin, a P. aeruginosa-derived exotoxin that is capable of
inducing neutrophil apoptosis [186], neutrophil extracellular trap
(NET) formation (NETosis) [187] (as discussed below in detail)
and type III secretion-dependent oncosis [188]. Further abnor-
malities reported for CF neutrophils include catalase- and
MPO-dependent actions [189], oxidant release [190–193],
neutrophil apoptosis [157], Coronin-1-associated neutrophil
survival [156] and others not discussed here in detail [87,194–
196].
The phenotypical characterization of neutrophils in CF airways
is hampered by several facts: (i) heterogeneity among CF patients
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sputum (impeding sputum studies in CF infants younger than
about 5/6 years of age), (iii) pre-analytical processing of complex
airway fluid material (sputum, see [197] for details) and cleavage
of surface markers essential for neutrophil subtype characteriza-
tion. A few studies used advanced optimized flow cytometric
approaches to dissect airway neutrophil subpopulations [8,185,
198–200]. These studies provided evidence that CF airway
neutrophils contain different subphenotypes, which feature non-
canonical surface receptor expression characteristics, in particular
CXCR4, CD39, RAGE, CD114 and CCR5. The functional and
pathophysiological relevance of these CF airway-site specific
neutrophil phenotypes remains to be defined [195,198,201].
Neutrophils at the pulmonary site of inflammation are
instrumentalized with three main anti-bacterial weapons:
phagocytosis, granule release and NET formation [202],
which are employed depending on the duration and severity
of host–pathogen interactions (Fig. 2). There is evidence for
impaired phagocytosis [150] and release of protease-rich
primary granules [148] in CF neutrophils as discussed above
and summarized in Table 1. When neutrophils at the pulmonary
site of host–pathogen interaction are unable to cope with the
encountered pathogen by phagocytosis or granule attack, they
employ their final armamentarium which is their own DNA.
Upon prolonged stimulation, neutrophils release NETs, which
are DNA fibers that entangle, immobilize and kill mainlyFig. 2. Neutrophil flexibility in CF. When neutrophils in CF airways are exposed to P
duration and the severity of the PAMP/DAMP contact. Neutrophils rapidly phagocyt
an intrinsic phagocytotic dysregulation depending on phagolysosomal chlorination. E
neutrophils feature an increased release of primary granules, while characteristics of
studied so far. After prolonged stimulation, NETs are generated to entangle extracell
control peripheral blood neutrophils.bacterial and fungal pathogens. The mechanisms by which
NETs kill the captured and immobilized bacteria are still not
fully understood, but histones and granule proteins, such as
proteases and calprotectin, could play a role [203,204]. CF
airway fluids feature abundant extracellular DNA [205] and the
amount of free extracellular DNA shows an association with
pulmonary function [206–209], supporting the concept that
recombinant DNases act beneficially in CF lung disease by
cleaving the NET-DNA meshwork and thereby facilitating
mucociliary clearance of cleaved DNA strands. NETs in the CF
airway context are mainly formed upon contact with P.
aeruginosa and a recent study nicely demonstrates that NETs
are capable of killing P. aeruginosa bacteria [210]. The CFTR
gene defect does not seem to affect NET-otic killing, since no
difference between CF and non-CF neutrophils were found
[210]. Intriguingly, isogenic clinical P. aeruginosa isolates
from CF patients exhibited an acquired resistance towards
NET-mediated killing, which correlated with the mucoid
phenotype, but was not a direct result of excess alginate
production [210]. NET formation seems to be critically
involved in the host defense against other CF-associated
pathogens, such as A. fumigatus [211] and this interaction
may be essential for the common A. fumigatus colonization in
CF patients.
Traditionally, neutrophils have been traditionally described to
be devoid of CFTR expression. However, recent studies indicateAMPs and/or DAMPs, distinct effector functions are activated depending on the
ose bacteria. As CFTR is localized in the phagolysosome, CF neutrophils feature
xtracellular pathogens and tissue structures are attacked by granule release. CF
secondary and tertiary granules in CF versus healthy neutrophils have not been
ular bacteria and fungi. NET formation capacity does not differ between CF and
Table 1
Immune cells in CF lung disease.
Immune cell Functional role Impairment in CF lung disease
Neutrophils • Anti-bacterial and -fungal host defense
• Cytokine/chemokine release
• Impaired chlorination/intracellular killing of phagocytosed bacteria
• Delayed apoptosis
• Impaired phagocytosis a
• Proteolytic and oxidative tissue damage
• Cleavage of leukocyte surface receptors
• DNA release (necrosis/NETosis)
• Increased elastase release
• Enhanced chemotaxis
Macrophages/monocytes • Anti-bacterial and ‐fungal host defense




• Increased secretion of pro-inflammatory cytokines
• Impaired intracellular killing of bacteria a
• Defective phagolysosomal acidification a
• Disturbed ceramide metabolism
• Dysregulated TLR4 trafficking
• Downregulated autophagy
•Macrophages: hyper-responsiveness towards LPS
•Monocytes: downregulation of TREM/hyporesponsiveness to LPS
•M1/M2 dysregulation a
• Reduced expression of scavenger receptors
• Cleavage of phosphatidylserine receptors/impaired efferocytosis
T cells • Anti-bacterial, -fungal and ‐viral host defense
• Antibody production
• Neutrophil recruitment (Th17)
• Allergic responses (ABPA, Th2)
• Immune regulation (Tregs)
• CFTR-mediated Th2 shift
• Pseudomonas aeruginosa-mediated Th2 shift
• Th17 activation
• Pseudomonas aeruginosa-mediated impairment of T cell proliferation
a Controversial studies.
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These studies demonstrate that CF neutrophils are defective in
chlorination of phagocytosed bacteria and further suggest that
CFTR as chloride channel is involved in the MPO-hydrogen
peroxide–chloride-mediated microbicidal function, relevant for
killing of P. aeruginosa [145,146]. These studies using primary
human neutrophils were extended by showing that iRNA-
mediated knock-down of CFTR in neutrophil-like immortalized
HL-60 cells impairs microbicidal effector functionalities [212]
and by demonstrating that Zebrafish with reduced cftr expression
featured impaired respiratory burst and neutrophil migration
[213]. The potential role of CFTR in neutrophils has been further
supported by studies in mice. Upon pharmacologic or genetic
inhibition/deletion of CFTR in neutrophils, pro-inflammatory
pathways (NF-κB, MIP-2 and TNF-α) were enhanced and
reconstitution of wild-type mice with cftr F508del neutrophils
showed increased pulmonary inflammation after LPS challenge
[214]. What is currently completely unknown is the turnover/
survival of neutrophils in the CF airway microenvironment.
Recent studies challenged the paradigm that neutrophils are
short-lived cells and showed, using sophisticated in vivo
neutrophil labeling methodology, that neutrophils live for
5.4 days in healthy individuals [215]. Future studies are required
to assess the neutrophil turnover/life-span in CF airways to
evaluate the effects of currently used anti-inflammatory drugs,
such as corticosteroids and ibuprofen, in CF patients.
In summary, the neutrophil is quantitatively the predominant
cell in the airways of CF lung disease and contributes to disease
progression through release of oxidants, proteases and other
proteins. A major challenge for future studies in the field will
be the in-depth characterization of neutrophil turnover andsubset functionality in CF lung disease in order to identify
specific neutrophil subtypes relevant for disease monitoring
and therapeutic targeting.
4.2. Macrophages and dendritic cells
Alveolar macrophages (MΦs), together with the epithelium,
are part of the lung's innate cellular surveillance system. MΦs
efficiently phagocytize bacteria, dead cells and debris and MΦ's
activation by external triggers (viruses, bacteria, bacterial prod-
ucts, etc.) leads to a cascade of events that contribute to the
migration of neutrophils into the alveolar space and, eventually,
to the activation of dendritic cells and T cells, initiating the
adaptive arm of immune response.
The number of alveolar MΦs in young, noninfected CF
patients has been reported to be elevated compared to non-CF
individual controls [125], suggesting a constitutive/intrinsic and
early mononuclear inflammation in CF. The high number of
MΦs in CF BAL correlated with an increased concentration of
the monocyte chemoattractant chemokine (MCP-1) CCL2
[124,125]. A similar phenotype is observed in the BAL of
several CF mouse models [216,217]. During an inflammatory
response, MΦs are differentiated toward distinct subpopulations,
which have different functionalities [218]. The so-termed
“classically” or “M1” MΦs represent inflammatory cells that
produce high amounts of pro-inflammatory cytokines and have
accentuated anti-microbial activity. M1 MΦs are generally
polarized by exposure to pathogen products (e.g. LPS) and
interferon-gamma (INF-γ). The “alternatively” (M2) activated
MΦs instead have an immunomodulating function, and promote
tissue remodeling and repair after an inflammatory stress
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also mediate chronic inflammation and tissue fibrosis. M2 MΦs
are polarized by cytokines that are characterized by a T helper
(Th) 2 response, such as IL-4 IL-13 or IL-10. Adequate activation
of an inflammatory response and the subsequent resolution
requires the balanced and coordinated activity of both MΦs
subpopulations. There has been some attempt to study MΦs
polarization in CF patients, however, results are inconclusive so
far. Circulating CF monocytes [219] and macrophages isolated
from BAL fluid from P. aeruginosa infected CF patients [220]
exhibited a M2 phenotype compared to controls, while MΦs
isolated fromCF nasal polyp explants showed aM1 profile [221].
Studies on murine CF alveolar MΦs suggest that these cells, in
the absence of any inflammatory triggers, express an M1
polarization profile, and therefore remain in a pro-inflammatory
state. Murine CF alveolar MΦs showed an exacerbated
expression of M1 activation markers when polarized with LPS/
INF-γ; the M2 activation also tends to be elevated in CF MΦs
[222]. In a subsequent study, it has been reported that, in
comparison to healthy controls, the analysis of MΦs isolated
from induced sputum of CF patients revealed a pronounced
expansion of a unique small CD14+ DR+ CD68dim population
characterized by reduced expression of the scavenger receptors
macrophage receptor with collagenous structure (MARCO) and
CD206 (mannose receptor). The authors speculate that MΦs with
altered plasma membrane receptor profile may lead to impaired
clearance of inhaled particles and apoptotic cell, and increased
inflammation and damage in CF lungs [124]. Thus, MΦs from
CF lungs display differences in number and phenotype, which
can be the result of exposure to the CF lung environment and/or
of cell-intrinsic/autonomous CF MΦs defects.
Based on these observations of skewed macrophage phe-
notypes in CF, the questions arise whether these changes are
just reflecting inflammation and infection in CF or whether
macrophages directly contribute to the pathogenesis of CF lung
disease? The creation of stable bone marrow (BM) chimeras, in
which WT and CF mice were exposed to total body irradiation,
transplanted with either WT BM or CF BM and, 3 months later
challenged with LPS, demonstrated that the enhanced secretion
of pro-inflammatory cytokines (most of which are abundantly
secreted by macrophages) depended on the lack of functional
CFTR in immune rather than resident epithelial cells. In
contrast, the exuberant migration of neutrophils in the airspace
derived from the absence of CFTR in both epithelial cells and
immune cells [217]. These data were elegantly corroborated on
a myeloid specific Cftr−/− mouse model generated by the
Cre-recombinase LoxP system in which Cftr exon 10 was
floxed under the control of the myeloid specific promoter
lysozyme. After 10 days of exposure with P. aeruginosa
intra-tracheally, the myeloid specific deletion of Cftr featured
an impaired ability to resolve infection and inflammation with
an increased number of BAL cells, increased concentration of
pro-inflammatory cytokines, reduced survival, greater weight
loss, and more severe clinical and lung pathology scores
compared to controls [223]. The contribution of CF MΦs to the
P. aeruginosa-related lung pathology was milder in a CF
mouse model (G551D−/G551D−) in which the tissue specificexpression of functional Cftr was achieved by gene comple-
mentation [224]. When viewed in combination, these studies
provide experimental evidence supporting the notion that
immune cells actively contribute to CF-related lung disease.
The question arises which dysfunctions characterize CF
MΦs? In CF pigs [225], a model that is greatly helping to
increase our knowledge of disease progression, a bacterial
clearance defect establishes from the time of birth, suggesting
that non-functional CFTR gives rise to a primary host response
defect, despite that total cells, numbers of neutrophils and
CXCL8 levels did not differ between CF and control pigs.
In-depth immunological studies will be essential to dissect the
various components of the innate immune system and their
potential impairment in CF pigs.
Although changes in the CF lung environment, such as
decreased secretion of anti-bactericidal molecules by submucosal
gland and epithelial cells; abnormal ASL ion composition and
pH, may contribute to this defect, there is evidence that absence
of functional CFTR leads to impaired bacterial killing in murine
[226–229] and human [230] MΦs, suggesting that reduced MΦ
bactericidal activity may impair the maintenance of CF lung
sterility. Macrophages also play a crucial role in the production of
cytokines during the innate immune response. Human [231,232]
and murine [217,222,233,234] CF MΦs were found to be
hyper-responsive when exposed to the bacterial endotoxin LPS,
with enhanced signal transduction through the NF-κB and
MAPK pathways [231,232,234], increased secretion of pro-
inflammatory cytokines [217,232,233] and alteration of LPS-
induced metabolic pathways (e.g. PPAR/LXR) [234]. Interest-
ingly, secretion of pro-inflammatory cytokines was correlated with
the amount of functional CFTR, as MΦs isolated from obligated
carriers [231] or from mice heterozygous for the Cftr-null allele
[217] had a concentration of inflammatory cytokines between
non-affected and CF-affected cells. In contrast, murine CF MΦs
exposed to P. aeruginosa for 2 hours did not differ in chemokine
secretion [28]. These studies indicate that the CF MΦ's hyper-
responsiveness to bacterial products may contribute to the
exuberant migration of other immune cells to the lungs and,
therefore, to the resulting lung damage.
Based on these studies, it remains to be considered whether
MΦs express functional CFTR and whether the observed MΦ
phenotypes in CF are cell-intrinsic. The expression of CFTR in
non-epithelial tissues has been described [235], however, the
impact of non-functional CFTR in non-epithelial cells is
becoming better understood with the recent development of a
mouse model in which the expression of CFTR can be
abolished in a tissue-specific manner. At low levels, the
CFTR protein is detectable in both murine MΦs [227,229] and
human MΦs [236] and the CFTR-like Cl− conductance has
been recorded in monocytes/MΦs [228–230,232,236], sug-
gesting that in these cells CFTR functions as a cAMP-
dependent chloride channel. In addition, inhibition of function-
al CFTR in wild-type MΦs led to a phenotype that resembles
CF MΦs [227,230,232]. Thus, CF MΦs express functional
CFTR, suggesting that CF MΦs dysfunctions are cell-
autonomous rather than a consequence of MΦs exposure to
the CF lung surrounding micromilieu.
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CFTR, it remains to be discussed by which mechanisms
non-functional CFTR leads to MΦ' dysfunctions. It has been
proposed that CF MΦs fail to kill bacteria due to defective
phagolysosome acidification as a result of a Cl−-related
electrogenic imbalance [227,228]. However, this finding was
challenged by other investigators showing that phagolysosomal
acidification in MΦ was not dependent on CFTR channel
activity [237]. In a more complex scenario, the alteration of the
pH in cellular vesicles led to the malfunction of a pH-sensitive
enzyme (acid sphingomyelinase) involved in ceramide metab-
olism. The release of ceramide during P. aeruginosa infection
in alveolar MΦs favors the formation of ceramide-enriched
membrane platforms, which mediates the assembly and ac-
tivation of the NADPH oxidase [28]. This complex triggers the
production of reactive oxygen species, which, in turn, favor the
killing of P. aeruginosa. In CF MΦs, ceramide has been shown
to accumulate in vesicles, impairing the formation of ceramide-
rich membrane platforms and activation of the NADPH
complex. However, the role of CFTR in controlling vesicle
pH remains controversially discussed [238,239]; discrepancies
that are likely due to differences in experimental settings. An
additional observation is that the phagosome Cl− concentration
can modulate the behavior of intracellular bacteria by altering
bacterial protein activity or host factors. For instance, the
CFTR-mediated Cl− flux in MΦs contributes to the
L. monocytogenes phagosomal escape to the host cytosol by
favoring its hemolytic activity [229]. In addition, the defective
CFTR-mediated Cl− flux in CF MΦs was found to impair
autophagy and autophagosome formation during B. cepacia
infection. CF mouse MΦs infected with B. cepacia down-
regulated the expression of autophagy-related genes compared
to WT cells, impairing the autophagosome–lysosome fusion
and thus reducing bacterial clearance. Prolonged B. cepacia
survival in CF MΦs has been associated with increased
secretion of the pro-inflammatory cytokine IL-1β [226]. CF
MΦs are also characterized by defective endosomes to
late-endosome/lysosome maturation during LPS challenge.
This defect was shown to lead to dysregulated TLR4 trafficking
from the plasma membrane to the lysosomes, where the
activated TLR4 is degraded. As a result, CF MΦs were
shown to feature a more robust TLR4 signaling with an
increased secretion of pro-inflammatory cytokines compared to
WT cells [232]. Studies analyzing human monocytes in CF
patients and control subjects found that the receptor Triggering
receptor expressed on myeloid cells 1 (TREM1) was down-
regulated on circulating CF monocytes and that this was
associated with circulating PAMPs and an unresponsiveness/
tolerance state toward LPS in CF [240,241]. This finding is in
contrast to studies using murine CFTR−/− or human CF patient
macrophages. The underlying reasons are not fully understood,
but based on the notion that monocytes upregulate a large array
of genes upon entering the airways and differentiation to
alveolar macrophages [242], it is conceivable that this dif-
ferentiation process modulates the CFTR-related respon-
siveness towards PAMPs and DAMPs. Nevertheless, these
discrepant observations necessitate future studies in the field ofmonocytes/macrophages in CF, utilizing both murine and
human experimental systems.
Macrophages represent the main scavengers of apoptotic
neutrophils, a process termed efferocytosis [243]. Efferocytosis is
essential in compartments where large numbers of neutrophils
accumulate and undergo aging and apoptosis, such as the CF
airways where large numbers of neutrophils undergo several
forms of apoptosis and cell death [244]. Successful efferocytosis
prevents secondary necrosis and pro-inflammatory cascades and
thereby acts as an anti-inflammatory. Notably, previous studies
found that clearance of apoptotic cells is impaired in the CF
microenvironment due to elastase-mediated cleavage of phos-
phatidylserine receptors or other CFTR-related mechanisms in
epithelial cells [245–247]. These findings underpin the complex-
ity of the initiation, maintenance, resolution and perpetuation of
neutrophilic inflammation in CF. Fig. 3 summarizes the complex
role and paracrine interaction partners of macrophages in CF lung
disease.
CF-DCs challenged with P. aeruginosa were found to exhibit
an abnormal expression of genes involved in the maintenance of
membrane structure and lipid-metabolism; in addition, CF DCs
displayed a delay in the early phase of differentiation [248,249].
On the other hand, neutrophil elastase in CF airway fluids was
found to inhibit DC maturation and functionality by shedding
CD86 and impairing antigen presentation capabilities [250]. In
combination, these data suggests that in CF, the cross-talk
between the innate and the adaptive immune response, orches-
trated by DCs, may also be compromised, caused by CFTR-
dependent and CFTR-independent proteolytic mechanisms.
More studies are needed to dissect the role of this arm of the
immune system in the development of CF lung disease.
Taken together, these observations suggest that CF MΦs
display several cell-autonomous/intrinsic dysfunctionalities that
alter their ability to properly control their response to in-
flammatory triggers and to kill bacteria in the context of CF
lung disease. In the early stages of CF lung disease, the
inappropriate MΦ behavior may contribute to conditions that
favor bacterial lung adaptation, harmful chronic infection, and
lung damage.
5. Th17 cells link innate and adaptive immunity
While neutrophils are the dominant cell population in the
broncho-alveolar compartment (bronchialN alveolar), recent
studies indicate that T cells accumulate within the subepithelial
bronchial tissue but are almost devoid of the bronchial space
[251], supporting the notion that the pulmonary immune system
is compartmentalized and the role of T cells has probably been
under-appreciated in CF lung disease due to their paucity in
sputum or BALF [252–254].
In recent years, there have been significant advances in our
understanding of T cell subsets beyond the canonical Th1/Th2
paradigm. It is now widely accepted that a normal immune
system harbors a regulatory T cell population specialized for
immune suppression, as well as a Th17 cell subset that
mediates inflammatory processes and autoimmunity [255].
Th17 cells are CD4+ T cells that produce IL-17 cytokines
Fig. 3. Macrophage flexibility in CF. The figure illustrates the complex involvement of macrophages in host–pathogen and cell–cell interactions in CF lung disease.
CF macrophages are hyper-responsive when exposed to bacterial (such as P. aeruginosa derived) PAMPs, with enhanced signal transduction and increased secretion
of pro-inflammatory cytokines. Through secretion of cytokines, alveolar macrophages communicate with neutrophils, lymphocytes, dendritic cells and epithelial
cells, thereby orchestrating the outcome of the pulmonary immune response in CF. In addition, CF macrophages have been described to show defective intracellular
bacterial killing (controversial finding) and apoptotic cell removal (efferocytosis) activities. In summary, these dysfunctions may lead to altered paracrine signaling
within the CF lung environment.
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and regulate both granulopoesis and recruitment of neutrophils
into sites of inflammation, thereby linking innate and adoptive
immunity [256]. IL-17 signals through the IL-17 receptor
(IL-17R), a type I transmembrane protein which is ubiquitously
expressed in tissues. IL-17 can stimulate a number of different
cell types including macrophages, dendritic cells, endothelial
cells or fibroblasts to release effector molecules leading to
pathology [257]. Th17 cells are activated by IL-23, mainly
derived from dendritic cells and macrophages, as well as by
IL-6 and TGF-β [258].
There is a rapidly growing body of evidence that IL-17-related
pathways are involved in the immunopathogenesis of a broad
spectrum of inflammatory human disease conditions, including
multiple sclerosis, rheumatic diseases, inflammatory bowel
disease, asthma, and atopic dermatitis [259]. In the lungs, IL-17
has been shown to be crucial for maintaining control of host
defense against extracellular pathogens. It was demonstrated that
IL-17, and its driving factor IL-23, are important for maintaining
mucosal host defense against Klebsiella pneumoniae infection in
human bronchial epithelial cells. In mice, IL-17 and IL-23 are
involved in host responses to infection by gram-negative bacteria,
in particular Klebsiella, P. aeruginosa, Escherichia coli,
Salmonella and Bordetella species [256,260,261]. The potential
role of IL-17-related pathways in CF lung disease is now greatly
supported by a considerable number of recent studies [162,
262,263]. Of particular interest for CF lung disease may be theobservations that IL-23 and IL-17 mediate inflammatory
response to mucoid P. aeruginosa infection and are critical for
neutrophil inflammation [264]. The IL-23-driven recruitment of
neutrophil inflammation is, however, not uniquely dependent on
IL-17: newer studies suggest that in addition to IL-17 production
by γδT cells after IL-23 stimulation, neutrophil recruitment is
promoted by IL-23 independently of IL-17 in an early in-
flammation phase [265]. In human studies, IL-17 and IL-23 were
markedly elevated in BAL fluid or sputum of CF patients with
chronic P. aeruginosa colonization undergoing pulmonary ex-
acerbation as well as in explanted CF lungs [162,266,267]. A
more recent study likewise found substantially increased levels of
IL-17 protein and mRNA, and IL-23 in the sputum of stable CF
patients [268]. This observation was especially pronounced in
patients chronically infected with P. aeruginosa, further pointing
to an important role of IL-17 in the neutrophil inflammation of
CF lung disease.
Though Th17 cells are regarded as the major producer of
IL-17, other cellular sources have been associated with pro-
duction of IL-17 depending on the underlying pathology,
especially γδT cells, natural killer T cells and CD8+ T cells
[256]. Beyond these cell types, IL-17 protein was detected also in
eosinophils, mast cells, neutrophils and human blood monocytes
[266,267]. In CF, the complexity of IL-17-producing cells has
recently been nicely demonstrated by Tan and colleagues
analyzing endobronchial biopsies. They showed that IL-17 cell
counts were significantly increased in lung tissue of young
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Whereas Th17 cells were the predominant IL-17-producing cell
type in the airway walls of newly diagnosed as well as established
CF and non-CF bronchiectasis, other important sources of IL-17
were NKT cells (in end stage lung disease) and γδT cells.
IL-17-producing cell counts depended on severity, as young
children showed intermediate counts compared to end stage lung
disease. Immunohistochemistry staining of explanted CF lungs
suggested that IL-17 is increased in lower airways compared to
non-CF lung tissue, and that IL-17 production localizes to
neutrophils [266,267]. The observation that elevated numbers of
IL-17-producing cells are already found in early lung disease in
very young CF patients and the correlation of disease severity and
P. aeruginosa colonization to IL-17+ cells and IL-17 protein
levels in BAL fluid render IL-17 and associated cytokines
potentially interesting biomarkers for monitoring CF lung in-
flammation. In addition to their potential value as biomarkers,
IL-17-related cytokines such as anti-IL-17 or anti-IL-23 anti-
bodies may be therapeutic targets to modify pulmonary in-
flammation in CF.
However, great therapeutic caution needs to be applied in an
environment of enhanced infection susceptibility, as it is the CF
lung. Suppressing of one particular inflammatory pathway may
result in uncontrolled bacterial growth and severe pulmonary
exacerbation. For these reasons, a deep understanding of the
IL-17-related pathways in the context of CF lung disease is
critical to assess the potential implications of an anti-IL-17
therapy, or interventions targeting its cellular source. Beyond
Th17, previous studies provided evidence that lymphocytes
from CF patients exhibit a cytokine dysregulation with an
intrinsic Th2 bias [270,271] and increased Nuclear Factor of
Activated T Cell (NFAT) translocation due to the cellular
CFTR defect, a topic related to adaptive immunity that is
reviewed in greater detail in a recent review [34].6. Innate immunity in CF—any relevance?
Innate immunity in CF is a growing field of interest in both
basic and translational research. Within the previous years, it
turned out that the interplay between cellular and soluble,
CFTR-dependent and ‐independent and pathogen-associated and
sterile pathomechanisms are of higher complexity than previous-
ly expected. While the link between the basic CF defect and
innate immune inflammation is increasingly appreciated [272],
key questions on the survival, subsets and functionalities of
phagocytes in CF airways remain controversial.
Single nucleotide polymorphisms (SNPs) in genes involved in
innate immunity, such as mannose binding lectin 2 (MBL2)
[273–278], Transforming growth factor β (TGF-β) [279], CD14
[280], Interferon-related developmental regulator 1 (IFRD1)
[281] and others, as well as recent genome-wide association
studies add another layer of complexity [279,282,283]. Consid-
ering the manifold components and mechanisms of innate
immunity in CF lung disease, the question remains which
diagnostic or therapeutic relevance remains for the clini-
cian. Diagnostically, several immune proteins, proteasesor proteolytically-generated peptides, such as CXCL8/IL-8, IL-6,
TNF-α, YKL-40, TGF-β, PGP, HMGB1, AAT:CD16, elastase
or MMP-9 have been proposed as biomarkers for CF lung
disease, but their clinical usefulness requires further cross-
sectional multi-center and longitudinal studies to understand
their kinetics, treatment responses and comparing their reliability,
validity and cost-effectiveness. Therapeutic consequences seem
to be farer on the horizon and have to be implemented with great
caution [2,284–286], since interfering with innate immune
recruitment or effector mechanisms harbors the risk of disabling
innate host defense mechanisms and favoring bacterial and
fungal infections. Therefore, future studies dissecting the kinetics
and dynamics of the innate immune system in cells, mice, ferrets,
pigs and humans will be essential to identify specific cell
populations or released proteins that are worth targeting in a time-
and inflammation-specific manner in CF lung disease.
Acknowledgements
This work was supported by the NIH (HL102371-01A1 to
AG), CF Foundation (GAGGAR07A0 to AG), DFG (MA 2081/
3-3 and MA 2081/4-1 to MAM; Emmy Noether Programme HA
5274/3-1 to D.H.) and BMBF (DZL to MAM). We thank
Peter-Michael Weber for excellent image design.
References
[1] Pillarisetti N, Williamson E, Linnane B, Skoric B, Robertson CF,
Robinson P, et al. Infection, Inflammation, and Lung Function Decline in
Infants with Cystic Fibrosis. Am J Respir Crit Care Med Jul 1
2011;184(1):75-81.
[2] Ratjen F. What's new in CF airway inflammation: an update. Paediatr
Respir Rev 2006;7(Suppl. 1):S70-2.
[3] Ratjen F. Diagnosing and managing infection in CF. Paediatr Respir Rev
2006;7(Suppl. 1):S151-3.
[4] Sagel SD, Dowell EB, Accurso FJ. Bacterial colonization and infection
in the CF lung. Methods Mol Med 2002;70:433-46.
[5] Knowles MR, Boucher RC. Mucus clearance as a primary innate defense
mechanism for mammalian airways. J Clin Invest Mar 2002;109(5):
571-7.
[6] Mall MA. Role of cilia, mucus, and airway surface liquid in mucociliary
dysfunction: Lessons from mouse models. J Aerosol Med Pulm Drug
Deliv Mar 2008;21(1):13-24.
[7] Bals R, Weiner DJ, Wilson JM. The innate immune system in cystic
fibrosis lung disease. J Clin Invest Feb 1999;103(3):303-7.
[8] Koller B, Bals R, Roos D, Korting HC, Griese M, Hartl D. Innate
immune receptors on neutrophils and their role in chronic lung disease.
Eur J Clin Invest Jul 2009;39(7):535-47.
[9] Greene CM, Carroll TP, Smith SGJ, Taggart CC, Devaney J, Griffin S,
et al. TLR-induced inflammation in cystic fibrosis and non-cystic fibrosis
airway epithelial cells. J Immunol Feb 1 2005;174(3):1638-46.
[10] Thelin WR, Kesimer M, Tarran R, Kreda SM, Grubb BR, Sheehan JK,
et al. The cystic fibrosis transmembrane conductance regulator is
regulated by a direct interaction with the protein phosphatase 2A. J
Biol Chem Dec 16 2005;280(50):41512-20.
[11] Kreda SM, Mall M, Mengos A, Rochelle L, Yankaskas J, Riordan JR,
et al. Characterization of wild-type and Delta F508 cystic fibrosis
transmembrane regulator in human respiratory epithelia. Mol Biol Cell
May 2005;16(5):2154-67.
[12] Anderson MP, Berger HA, Rich DP, Gregory RJ, Smith AE, Welsh MJ.
Nucleoside Triphosphates Are Required to Open the Cftr Chloride
Channel. Cell Nov 15 1991;67(4):775-84.
376 D. Hartl et al. / Journal of Cystic Fibrosis 11 (2012) 363–382[13] Anderson MP, Gregory RJ, Thompson S, Souza DW, Paul S, Mulligan
RC, et al. Demonstration That Cftr Is a Chloride Channel by Alteration of
Its Anion Selectivity. Science Jul 12 1991;253(5016):202-5.
[14] Caputo A, Caci E, Ferrera L, Pedemonte N, Barsanti C, Sondo E, et al.
TMEM16A, a membrane protein associated with calcium-dependent
chloride channel activity. Science Oct 24 2008;322(5901):590-4.
[15] Stutts MJ, Canessa CM, Olsen JC, Hamrick M, Cohn JA, Rossier BC,
et al. Cftr as a Camp-Dependent Regulator of Sodium-Channels. Science
Aug 11 1995;269(5225):847-50.
[16] Mall MA. Role of the amiloride-sensitive epithelial Na+ channel in the
pathogenesis and as a therapeutic target for cystic fibrosis lung disease.
Exp Physiol Feb 2009;94(2):171-4.
[17] Matsui H, Grubb BR, Tarran R, Randell SH, Gatzy JT, Davis CW, et al.
Evidence for periciliary liquid layer depletion, not abnormal ion
composition, in the pathogenesis of cystic fibrosis airways disease. Cell
Dec 23 1998;95(7):1005-15.
[18] Tarran R, Button B, Boucher RC. Regulation of normal and cystic
fibrosis airway surface liquid volume by phasic shear stress. Annu Rev
Physiol 2006;68:543-61.
[19] Zhou Z, Duerr J, Johannesson B, Schubert SC, Treis D, Harm M, et al.
The ENaC-overexpressing mouse as a model of cystic fibrosis lung
disease. J Cyst Fibros Jun 2011;10(Suppl. 2):S172-82.
[20] Wilke M, Buijs-Offerman RM, Aarbiou J, Colledge WH, Sheppard DN,
Touqui L, et al. Mouse models of cystic fibrosis: phenotypic analysis and
research applications. J Cyst Fibros Jun 2011;10(Suppl. 2):S152-71.
[21] Davidson DJ, Dorin JR. The CF mouse: an important tool for studying
cystic fibrosis. Expert Rev Mol Med Mar 12 2001;2001:1–27.
[22] Davidson DJ, Rolfe M. Mouse models of cystic fibrosis. Trends Genet
Oct 2001;17(10):S29-37.
[23] Grubb BR, Boucher RC. Pathophysiology of gene-targeted mouse
models for cystic fibrosis. Physiol Rev Jan 1999;79(1 Suppl):S193-214.
[24] Mall M, Grubb BR, Harkema JR, O'Neal WK, Boucher RC. Increased
airway epithelial Na+ absorption produces cystic fibrosis-like lung
disease in mice. Nat Med May 2004;10(5):487-93.
[25] Mall MA, Harkema JR, Trojanek JB, Treis D, Livraghi A, Schubert S,
et al. Development of chronic bronchitis and emphysema in
beta-epithelial Na+ channel-overexpressing mice. Am J Respir Crit
Care Med Apr 1 2008;177(7):730-42.
[26] Zhou Z, Treis D, Schubert SC, Harm M, Schatterny J, Hirtz S, et al.
Preventive but not late amiloride therapy reduces morbidity and mortality
of lung disease in betaENaC-overexpressing mice. Am J Respir Crit Care
Med Dec 15 2008;178(12):1245-56.
[27] Teichgraber V, Ulrich M, Endlich N, Riethmuller J, Wilker B, De
Oliveira-Munding CC, et al. Ceramide accumulation mediates inflam-
mation, cell death and infection susceptibility in cystic fibrosis. Nat Med
Apr 2008;14(4):382-91.
[28] Zhang Y, Li X, Grassme H, Doring G, Gulbins E. Alterations in
Ceramide Concentration and pH Determine the Release of Reactive
Oxygen Species by Cftr-Deficient Macrophages on Infection. J Immunol
May 1 2010;184(9):5104-11.
[29] Ulrich M, Worlitzsch D, Viglio S, Siegmann N, Iadarola P, Shute JK,
et al. Alveolar inflammation in cystic fibrosis. J Cyst Fibros May
2010;9(3):217-27.
[30] Campana S, Taccetti G, Ravenni N, Masi I, Audino S, Sisi B, et al.
Molecular epidemiology of Pseudomonas aeruginosa, Burkholderia
cepacia complex and methicillin-resistant Staphylococcus aureus in a
cystic fibrosis center. J Cyst Fibros Aug 2004;3(3):159-63.
[31] Doring G, Hoiby N. Early intervention and prevention of lung disease in
cystic fibrosis: a European consensus. J Cyst Fibros Jun 2004;3(2):
67-91.
[32] Chmiel JF, Berger M, Konstan MW. The role of inflammation in the
pathophysiology of CF lung disease. Clin Rev Allergy Immunol Aug
2002;23(1):5–27.
[33] Davis PB, Drumm M, Konstan MW. Cystic fibrosis. Am J Respir Crit
Care Med Nov 1996;154(5):1229-56.
[34] Ratner D, Mueller C. Immune responses in Cystic Fibrosis; are they
intrinsically defective? Am J Respir Cell Mol Biol Mar 2012;46(6):
715-22.[35] Ramsey BW, Davies J, McElvaney NG, Tullis E, Bell SC, Drevinek P,
et al. A CFTR potentiator in patients with cystic fibrosis and the G551D
mutation. N Engl J Med Nov 3 2011;365(18):1663-72.
[36] Accurso FJ, Rowe SM, Clancy JP, Boyle MP, Dunitz JM, Durie PR,
et al. Effect of VX-770 in persons with cystic fibrosis and the
G551D-CFTR mutation. N Engl J Med Nov 18 2010;363(21):
1991-2003.
[37] Hirtz S, Gonska T, Seydewitz HH, Thomas J, Greiner P, Kuehr J, et al.
CFTR Cl- channel function in native human colon correlates with the
genotype and phenotype in cystic fibrosis. Gastroenterology Oct
2004;127(4):1085-95.
[38] Roth EK, Hirtz S, Duerr J, Wenning D, Eichler I, Seydewitz HH, et al.
The K+ channel opener 1-EBIO potentiates residual function of mutant
CFTR in rectal biopsies from cystic fibrosis patients. PLoS One
2011;6(8):e24445.
[39] Moss RB. Allergic bronchopulmonary aspergillosis and Aspergillus
infection in cystic fibrosis. Curr Opin Pulm Med Nov 2010;16(6):
598-603.
[40] Chotirmall SH, O'Donoghue E, Bennett K, Gunaratnam C, O'Neill SJ,
McElvaney NG. Sputum Candida albicans presages FEV(1) decline and
hospital-treated exacerbations in cystic fibrosis. Chest Nov 2010;138(5):
1186-95.
[41] Cimon B, Carrere J, Vinatier JF, Chazalette JP, Chabasse D, Bouchara
JP. Clinical significance of Scedosporium apiospermum in patients with
cystic fibrosis. Eur J Clin Microbiol Infect Dis Jan 2000;19(1):53-6.
[42] Bendiak GN, Ratjen F. The approach to Pseudomonas aeruginosa in
cystic fibrosis. Semin Respir Crit Care Med Oct 2009;30(5):587-95.
[43] Hartl D. Immunological mechanisms behind the cystic fibrosis-ABPA
link. Med Mycol 2009;47:S183-91.
[44] Thursfield RM, Holden K, Bush A, Adams A, Nicholson AG. What Is
the Significance of Aspergillus Fumigatus in Bal in Children with Cystic
Fibrosis. Pediatr Pulmonol 2011:304-5.
[45] Hartl D, Griese M, Kappler M, Zissel G, Reinhardt D, Rebhan C, et al.
Pulmonary T(H)2 response in Pseudomonas aeruginosa-infected patients
with cystic fibrosis. J Allergy Clin Immunol 2006;117(1):204-11.
[46] Kawai T, Akira S. The role of pattern-recognition receptors in innate
immunity: update on Toll-like receptors. Nat Immunol May 2010;11(5):
373-84.
[47] Kawai T, Akira S. Toll-like Receptors and Their Crosstalk with Other
Innate Receptors in Infection and Immunity. Immunity May 27
2011;34(5):637-50.
[48] Takeuchi O, Akira S. Pattern Recognition Receptors and Inflammation.
Cell Mar 19 2010;140(6):805-20.
[49] Armstrong L, Medford AR, Uppington KM, Robertson J, Witherden IR,
Tetley TD, et al. Expression of functional toll-like receptor-2 and -4 on
alveolar epithelial cells. Am J Respir Cell Mol Aug 2004;31(2):241-5.
[50] Droemann D, Goldmann T, Branscheid D, Clark R, Dalhoff K, Zabel P,
et al. Toll-like receptor 2 is expressed by alveolar epithelial cells type II
and macrophages in the human lung. Histochem Cell Biol Feb
2003;119(2):103-8.
[51] Greene CM, Branagan P, McElvaney NG. Toll-like receptors as
therapeutic targets in cystic fibrosis. Expert Opin Ther Targets Dec
2008;12(12):1481-95.
[52] Muir A, Soong G, Sokol S, Reddy B, Gomez MI, Van Heeckeren A,
et al. Toll-like receptors in normal and cystic fibrosis airway epithelial
cells. Am J Respir Cell Mol Jun 2004;30(6):777-83.
[53] Latz E, Schoenemeyer A, Visintin A, Fitzgerald KA, Monks BG, Knetter
CF, et al. TLR9 signals after translocating from the ER to CpG DNA in
the lysosome. Nat Immunol Feb 2004;5(2):190-8.
[54] Platz J, Beisswenger C, Dalpke A, Koczulla R, Pinkenburg O,
Vogelmeier C, et al. Microbial DNA induces a host defense reaction of
human respiratory epithelial cells. J Immunol Jul 15 2004;173(2):
1219-23.
[55] Greene CM, Carroll TP, Smith SG, Taggart CC, Devaney J, Griffin S,
et al. TLR-induced inflammation in cystic fibrosis and non-cystic fibrosis
airway epithelial cells. J Immunol Feb 1 2005;174(3):1638-46.
[56] Adamo R, Sokol S, Soong G, Gomez MI, Prince A. Pseudomonas
aeruginosa flagella activate airway epithelial cells through asialoGM1
377D. Hartl et al. / Journal of Cystic Fibrosis 11 (2012) 363–382and toll-like receptor 2 as well as toll-like receptor 5. Am J Respir Cell
Mol Biol May 2004;30(5):627-34.
[57] Monick MM, Yarovinsky TO, Powers LS, Butler NS, Carter AB,
Gudmundsson G, et al. Respiratory syncytial virus up-regulates TLR4
and sensitizes airway epithelial cells to endotoxin. J Biol Chem Dec 26
2003;278(52):53035-44.
[58] Soong G, Reddy B, Sokol S, Adamo R, Prince A. TLR2 is mobilized into
an apical lipid raft receptor complex to signal infection in airway
epithelial cells. J Clin Invest May 2004;113(10):1482-9.
[59] Muir A, Soong G, Sokol S, Reddy B, Gomez MI, Van Heeckeren A,
et al. Toll-like receptors in normal and cystic fibrosis airway epithelial
cells. Am J Respir Cell Mol Biol Jun 2004;30(6):777-83.
[60] Hauber HP, Tulic MK, Tsicopoulos A, Wallaert B, Olivenstein R,
Daigneault P, et al. Toll-like receptors 4 and 2 expression in the bronchial
mucosa of patients with cystic fibrosis. Can Respir J Jan-Feb 2005;12(1):
13-8.
[61] John G, Yildirim AO, Rubin BK, Gruenert DC, Henke MO.
TLR-4-mediated innate immunity is reduced in cystic fibrosis airway
cells. Am J Respir Cell Mol Biol Apr 2010;42(4):424-31.
[62] John G, Chillappagari S, Rubin BK, Gruenert DC, Henke MO. Reduced
surface toll-like receptor-4 expression and absent interferon-gamma-inducible
protein-10 induction in cystic fibrosis airway cells. Exp Lung Res Aug
2011;37(6):319-26.
[63] Cohen TS, Prince A. Cystic fibrosis: a mucosal immunodeficiency
syndrome. Nat Med 2012;18(4):509-19.
[64] Zhang Z, Louboutin JP, Weiner DJ, Goldberg JB, Wilson JM. Human
airway epithelial cells sense Pseudomonas aeruginosa infection via
recognition of flagellin by Toll-like receptor 5. Infect Immun Nov
2005;73(11):7151-60.
[65] de CVGM, Le Goffic R, Balloy V, Plotkowski MC, Chignard M,
Si-Tahar M. TLR 5, but neither TLR2 nor TLR4, is involved in lung
epithelial cell response to Burkholderia cenocepacia. FEMS Immunol
Med Microbiol Oct 2008;54(1):37-44.
[66] Blohmke CJ, Victor RE, Hirschfeld AF, Elias IM, Hancock DG, Lane CR,
et al. Innate immunity mediated by TLR5 as a novel antiinflammatory
target for cystic fibrosis lung disease. J Immunol Jun 1 2008;180(11):
7764-73.
[67] Blohmke CJ, Park J, Hirschfeld AF, Victor RE, Schneiderman J,
Stefanowicz D, et al. TLR5 as an anti-inflammatory target and modifier
gene in cystic fibrosis. J Immunol Dec 15 2010;185(12):7731-8.
[68] Roussel L, Martel G, Berube J, Rousseau S. P. aeruginosa drives CXCL8
synthesis via redundant toll-like receptors and NADPH oxidase in
CFTRF508 airway epithelial cells. J Cyst Fibros Mar 2011;10(2):107-13.
[69] Chotirmall SH, Branagan P, Gunaratnam C, McElvaney NG.
Aspergillus/allergic bronchopulmonary aspergillosis in an Irish cystic
fibrosis population: a diagnostically challenging entity. Respir Care Aug
2008;53(8):1035-41.
[70] Beisswenger C, Hess C, Bals R. Aspergillus fumigatus conidia induce
interferon-beta signalling in respiratory epithelial cells. Eur Respir J Feb
2012;39(2):411-8.
[71] Da Silva CA, Hartl D, Liu W, Lee CG, Elias JA. TLR-2 and IL-17A in
chitin-induced macrophage activation and acute inflammation. J
Immunol Sep 15 2008;181(6):4279-86.
[72] Walsh DE, Greene CM, Carroll TP, Taggart CC, Gallagher PM, O'Neill
SJ, et al. Interleukin-8 up-regulation by neutrophil elastase is mediated
by MyD88/IRAK/TRAF-6 in human bronchial epithelium. J Biol Chem
Sep 21 2001;276(38):35494-9.
[73] Devaney JM, Greene CM, Taggart CC, Carroll TP, O'Neill SJ,
McElvaney NG. Neutrophil elastase up-regulates interleukin-8 via
toll-like receptor 4. FEBS Lett Jun 5 2003;544(1–3):129-32.
[74] Shao MX, Nadel JA. Neutrophil elastase induces MUC5AC mucin
production in human airway epithelial cells via a cascade involving
protein kinase C, reactive oxygen species, and TNF-alpha-converting
enzyme. J Immunol Sep 15 2005;175(6):4009-16.
[75] Bergin DA, Greene CM, Sterchi EE, Kenna C, Geraghty P, Belaaouaj A,
et al. Activation of the epidermal growth factor receptor (EGFR) by a
novel metalloprotease pathway. J Biol Chem Nov 14 2008;283(46):
31736-44.[76] Cosgrove S, Chotirmall SH, Greene CM, McElvaney NG. Pulmonary
proteases in the cystic fibrosis lung induce interleukin 8 expression from
bronchial epithelial cells via a heme/meprin/epidermal growth factor
receptor/Toll-like receptor pathway. J Biol Chem Mar 4 2011;286(9):
7692-704.
[77] Chotirmall SH, Greene CM, Oglesby IK, Thomas W, O'Neill SJ, Harvey
BJ, et al. 17Beta-estradiol inhibits IL-8 in cystic fibrosis by up-regulating
secretory leucoprotease inhibitor. Am J Respir Crit Care Med Jul 1
2010;182(1):62-72.
[78] Taggart CC, Greene CM, McElvaney NG, O'Neill S. Secretory
leucoprotease inhibitor prevents lipopolysaccharide-induced IkappaBalpha
degradation without affecting phosphorylation or ubiquitination. J Biol
Chem Sep 13 2002;277(37):33648-53.
[79] Greene CM, McElvaney NG, O'Neill SJ, Taggart CC. Secretory
leucoprotease inhibitor impairs Toll-like receptor 2- and 4-mediated
responses in monocytic cells. Infect Immun Jun 2004;72(6):3684-7.
[80] Taggart CC, Cryan SA, Weldon S, Gibbons A, Greene CM, Kelly E,
et al. Secretory leucoprotease inhibitor binds to NF-kappaB binding sites
in monocytes and inhibits p65 binding. J Exp Med Dec 19 2005;202(12):
1659-68.
[81] Oglesby IK, Bray IM, Chotirmall SH, Stallings RL, O'Neill SJ,
McElvaney NG, et al. miR-126 is downregulated in cystic fibrosis
airway epithelial cells and regulates TOM1 expression. J Immunol Feb
15 2010;184(4):1702-9.
[82] Gerard C, Rollins BJ. Chemokines and disease. Nat Immunol 2001;2(2):
108-15.
[83] Moser B, Loetscher P. Lymphocyte traffic control by chemokines. Nat
Immunol Feb 2001;2(2):123-8.
[84] Panina-Bordignon P, D'Ambrosio D. Chemokines and their receptors in
asthma and chronic obstructive pulmonary disease. Curr Opin Pulm Med
2003;9(2):104-10.
[85] Zemans RL, Briones N, Campbell M, McClendon J, Young SK, Suzuki
T, et al. Neutrophil transmigration triggers repair of the lung epithelium
via beta-catenin signaling. Proc Natl Acad Sci U S A Sep 20
2011;108(38):15990-5.
[86] Zemans RL, Colgan SP, Downey GP. Transepithelial migration of
neutrophils: mechanisms and implications for acute lung injury. Am J
Respir Cell Mol May 2009;40(5):519-35.
[87] Downey DG, Bell SC, Elborn JS. Neutrophils in cystic fibrosis. Thorax
Jan 2009;64(1):81-8.
[88] Russell KJ, McRedmond J, Mukherji N, Costello C, Keatings V, Linnane S,
et al. Neutrophil adhesion molecule surface expression and responsiveness in
cystic fibrosis. Am J Respir Crit Care Med Mar 1998;157(3):756-61.
[89] Downey DG, Brockbank S, Martin SL, Ennis M, Elborn JS. The effect of
treatment of cystic fibrosis pulmonary exacerbations on airways and
systemic inflammation. Pediatr Pulmonol Aug 2007;42(8):729-35.
[90] Tabary O, Corvol H, Boncoeur E, Chadelat K, Fitting C, Cavaillon JM,
et al. Adherence of airway neutrophils and inflammatory response are
increased in CF airway epithelial cell-neutrophil interactions. Am J
Physiol Lung Cell Mol Physiol Mar 2006;290(3):L588-96.
[91] Owen C. Chemokine receptors in airway disease: which receptors to
target? Pulm Pharmacol Ther 2001;14(3):193-202.
[92] Yang D, de la Rosa G, Tewary P, Oppenheim JJ. Alarmins link
neutrophils and dendritic cells. Trends Immunol Nov 2009;30(11):531-7.
[93] Yang D, Oppenheim JJ. Alarmins and antimicrobial immunity. Med
Mycol 2009;47(Suppl. 1):S146-53.
[94] Sagel SD, Accurso FJ. Monitoring inflammation in CF. Cytokines. Clin
Rev Allergy Immunol Aug 2002;23(1):41-57.
[95] Nichols D, Chmiel J, Berger M. Chronic inflammation in the cystic
fibrosis lung: alterations in inter- and intracellular signaling. Clin Rev
Allergy Immunol Apr 2008;34(2):146-62.
[96] Elizur A, Cannon CL, Ferkol TW. Airway inflammation in cystic
fibrosis. Chest Feb 2008;133(2):489-95.
[97] Le J, Vilcek J. Tumor necrosis factor and interleukin 1: cytokines with
multiple overlapping biological activities. Lab Invest Mar 1987;56(3):234-48.
[98] Yang M, Kumar RK, Hansbro PM, Foster PS. Emerging roles of
pulmonary macrophages in driving the development of severe asthma. J
Leukoc Biol Apr 2012;91(4):557-69.
378 D. Hartl et al. / Journal of Cystic Fibrosis 11 (2012) 363–382[99] Salva PS, Doyle NA, Graham L, Eigen H, Doerschuk CM. TNF-alpha,
IL-8, soluble ICAM-1, and neutrophils in sputum of cystic fibrosis
patients. Pediatr Pulmonol Jan 1996;21(1):11-9.
[100] Osika E, Cavaillon JM, Chadelat K, Boule M, Fitting C, Tournier G,
et al. Distinct sputum cytokine profiles in cystic fibrosis and other
chronic inflammatory airway disease. Eur Respir J Aug 1999;14(2):
339-46.
[101] Balfour-Lynn IM, Klein NJ, Dinwiddie R. Randomised controlled trial of
inhaled corticosteroids (fluticasone propionate) in cystic fibrosis. Arch
Dis Child Aug 1997;77(2):124-30.
[102] Colombo C, Faelli N, Tirelli AS, Fortunato F, Biffi A, Claut L, et al.
Analysis of inflammatory and immune response biomarkers in sputum
and exhaled breath condensate by a multi-parametric biochip array in
cystic fibrosis. Int J Immunopathol Pharmacol Apr-Jun 2011;24(2):
423-32.
[103] Dinarello CA. Interleukin-1 in the pathogenesis and treatment of
inflammatory diseases. Blood Apr 7 2011;117(14):3720-32.
[104] Wilmott RW, Frenzke M, Kociela V, Peng L. Plasma interleukin-1 alpha
and beta, tumor necrosis factor-alpha, and lipopolysaccharide concen-
trations during pulmonary exacerbations of cystic fibrosis. Pediatr
Pulmonol Jul 1994;18(1):21-7.
[105] Greally P, Hussain MJ, Vergani D, Price JF. Serum interleukin-1 alpha
and soluble interleukin-2 receptor concentrations in cystic fibrosis. Arch
Dis Child Jun 1993;68(6):785-7.
[106] Wilmott RW, Kassab JT, Kilian PL, Benjamin WR, Douglas SD, Wood
RE. Increased levels of interleukin-1 in bronchoalveolar washings from
children with bacterial pulmonary infections. Am Rev Respir Dis Aug
1990;142(2):365-8.
[107] Bonfield TL, Panuska JR, Konstan MW, Hilliard KA, Hilliard JB,
Ghnaim H, et al. Inflammatory Cytokines in Cystic-Fibrosis Lungs. Am J
Respir Crit Care Med Dec 1995;152(6):2111-8.
[108] Douglas TA, Brennan S, Gard S, Berry L, Gangell C, Stick SM, et al.
Acquisition and eradication of P. aeruginosa in young children with
cystic fibrosis. Eur Respir J Feb 2009;33(2):305-11.
[109] Bonfield TL, Konstan MW, Burfeind P, Panuska JR, Hilliard JB, Berger
M. Normal bronchial epithelial cells constitutively produce the
anti-inflammatory cytokine interleukin-10, which is downregulated in
cystic fibrosis. Am J Respir Cell Mol Biol Sep 1995;13(3):257-61.
[110] Muhlebach MS, Reed W, Noah TL. Quantitative cytokine gene
expression in CF airway. Pediatr Pulmonol May 2004;37(5):393-9.
[111] Buff SM, Yu H, McCall JN, Caldwell SM, Ferkol TW, Flotte TR, et al.
IL-10 delivery by AAV5 vector attenuates inflammation in mice with
Pseudomonas pneumonia. Gene Ther May 2010;17(5):567-76.
[112] Sagel SD. Noninvasive biomarkers of airway inflammation in cystic
fibrosis. Curr Opin Pulm Med Nov 2003;9(6):516-21.
[113] Bongartz T, Sutton AJ, Sweeting MJ, Buchan I, Matteson EL, Montori
V. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of
serious infections and malignancies: systematic review and meta-analysis
of rare harmful effects in randomized controlled trials. JAMA May 17
2006;295(19):2275-85.
[114] Charo IF, Ransohoff RM. The many roles of chemokines and chemokine
receptors in inflammation. N Engl J Med Feb 9 2006;354(6):610-21.
[115] Kunkel SL, Strieter RM, Chensue SW, Basha M, Standiford T, Ham J,
et al. Tumor necrosis factor-alpha, interleukin-8 and chemotactic
cytokines. Prog Clin Biol Res 1990;349:433-44.
[116] Winkler M. Role of cytokines and other inflammatory mediators. BJOG
Apr 2003;110(Suppl. 20):118-23.
[117] Hartl D, Latzin P, Hordijk P, Marcos V, Rudolph C, Woischnik M, et al.
Cleavage of CXCR1 on neutrophils disables bacterial killing in cystic
fibrosis lung disease. Nat Med Dec 2007;13(12):1423-30.
[118] Mayer-Hamblett N, Aitken ML, Accurso FJ, Kronmal RA, Konstan
MW, Burns JL, et al. Association between pulmonary function and
sputum biomarkers in cystic fibrosis. Am J Respir Crit Care Med Apr 15
2007;175(8):822-8.
[119] Sagel SD, Kapsner R, Osberg I, Sontag MK, Accurso FJ. Airway
inflammation in children with cystic fibrosis and healthy children
assessed by sputum induction. Am J Respir Crit Care Med Oct 15
2001;164(8):1425-31.[120] Dean TP, Dai Y, Shute JK, Church MK, Warner JO. Interleukin-8
concentrations are elevated in bronchoalveolar lavage, sputum, and sera
of children with cystic fibrosis. Pediatr Res Aug 1993;34(2):159-61.
[121] Karpati F, Hjelte FL, Wretlind B. TNF-alpha and IL-8 in consecutive
sputum samples from cystic fibrosis patients during antibiotic treatment.
Scand J Infect Dis 2000;32(1):75-9.
[122] Schmitt-Grohe S, Naujoks C, Bargon J, Wagner TO, Schubert R, Hippe
V, et al. Interleukin-8 in whole blood and clinical status in cystic fibrosis.
Cytokine Jan 7 2005;29(1):18-23.
[123] Mahler DA, Huang S, Tabrizi M, Bell GM. Efficacy and safety of a
monoclonal antibody recognizing interleukin-8 in COPD: a pilot study.
Chest Sep 2004;126(3):926-34.
[124] Rao S, Wright AK, Montiero W, Ziegler-Heitbrock L, Grigg J. Monocyte
chemoattractant chemokines in cystic fibrosis. J Cyst Fibros Mar
2009;8(2):97–103.
[125] Brennan S, Sly PD, Gangell CL, Sturges N, Winfield K, Wikstrom M,
et al. Alveolar macrophages and CC chemokines are increased in
children with cystic fibrosis. Eur Respir J Sep 2009;34(3):655-61.
[126] Estell K, Braunstein G, Tucker T, Varga K, Collawn JF, Schwiebert LM.
Plasma membrane CFTR regulates RANTES expression via its
C-terminal PDZ-interacting motif. Mol Cell Biol Jan 2003;23(2):
594-606.
[127] Schwiebert LM, Estell K, Propst SM. Chemokine expression in CF
epithelia: implications for the role of CFTR in RANTES expression. Am
J Physiol Mar 1999;276(3):C700-10 [Research Support, Non-U.S.
Gov't].
[128] Hafen GM, Hartl D, Regamey N, Casaulta C, Latzin P. Allergic
bronchopulmonary aspergillosis: the hunt for a diagnostic serological
marker in cystic fibrosis patients. Expert Rev Mol Diagn Mar 2009;9(2):
157-64.
[129] Hartl D, Buckland KF, Hogaboam CM. Chemokines in allergic
aspergillosis–from animal models to human lung diseases. Inflamm
Allergy Drug Targets 2006;5(4):219-28.
[130] Hartl D, Latzin P, Zissel G, Krane M, Krauss-Etschmann S, Griese M.
Chemokines indicate allergic bronchopulmonary aspergillosis in patients
with cystic fibrosis. Am J Respir Crit CareMed Jun 15 2006;173(12):1370-6.
[131] Hartl D, Lee CG, Da Silva CA, Chupp GL, Elias JA. Novel biomarkers
in asthma: chemokines and chitinase-like proteins. Curr Opin Allergy
Clin Immunol Feb 2009;9(1):60-6.
[132] Latzin P, Hartl D, Regamey N, Frey U, Schoeni MH, Casaulta C.
Comparison of serum markers for allergic bronchopulmonary aspergil-
losis in cystic fibrosis. Eur Respir J 2008;31(1):36-42.
[133] Djekic UV, Gaggar A, Weathington NM. Attacking the multi-tiered
proteolytic pathology of COPD: new insights from basic and transla-
tional studies. Pharmacol Ther Feb 2009;121(2):132-46.
[134] Rowe SM, Jackson PL, Liu G, Hardison M, Livraghi A, Solomon GM,
et al. Potential role of high-mobility group box 1 in cystic fibrosis airway
disease. Am J Respir Crit Care Med Oct 15 2008;178(8):822-31.
[135] Weathington NM, van Houwelingen AH, Noerager BD, Jackson PL,
Kraneveld AD, Galin FS, et al. A novel peptide CXCR ligand derived
from extracellular matrix degradation during airway inflammation. Nat
Med Mar 2006;12(3):317-23.
[136] Gaggar A, Jackson PL, Noerager BD, O'Reilly PJ, McQuaid DB, Rowe
SM, et al. A novel proteolytic cascade generates an extracellular
matrix-derived chemoattractant in chronic neutrophilic inflammation. J
Immunol Apr 15 2008;180(8):5662-9.
[137] Snelgrove RJ, Jackson PL, Hardison MT, Noerager BD, Kinloch A,
Gaggar A, et al. A critical role for LTA4H in limiting chronic pulmonary
neutrophilic inflammation. Science Oct 1 2010;330(6000):90-4.
[138] Bianchi ME, Manfredi AA. High-mobility group box 1 (HMGB1)
protein at the crossroads between innate and adaptive immunity.
Immunol Rev Dec 2007;220:35-46.
[139] Wang H, Bloom O, Zhang M, Vishnubhakat JM, Ombrellino M, Che J,
et al. HMG-1 as a late mediator of endotoxin lethality in mice. Science
Jul 9 1999;285(5425):248-51.
[140] Scaffidi P, Misteli T, Bianchi ME. Release of chromatin protein HMGB1
by necrotic cells triggers inflammation. Nature Jul 11 2002;418(6894):
191-5.
379D. Hartl et al. / Journal of Cystic Fibrosis 11 (2012) 363–382[141] Schiraldi M, Raucci A, Munoz LM, Livoti E, Celona B, Venereau E,
et al. HMGB1 promotes recruitment of inflammatory cells to damaged
tissues by forming a complex with CXCL12 and signaling via CXCR4. J
Exp Med Mar 12 2012;209(3):551-63.
[142] Gaggar A, Rowe SM, Matthew H, Blalock JE. Proline-Glycine-Proline
(PGP) and High Mobility Group Box Protein-1 (HMGB1): Potential
Mediators of Cystic Fibrosis Airway Inflammation. Open Respir Med J
2010;4:32-8.
[143] Mollinedo F, Borregaard N, Boxer LA. Novel trends in neutrophil
structure, function and development. Immunol Today Dec 1999;20(12):
535-7.
[144] Mantovani A, Cassatella MA, Costantini C, Jaillon S. Neutrophils in the
activation and regulation of innate and adaptive immunity. Nat Rev
Immunol Aug 2011;11(8):519-31.
[145] Painter RG, Bonvillain RW, Valentine VG, Lombard GA, LaPlace SG,
Nauseef WM, et al. The role of chloride anion and CFTR in killing of
Pseudomonas aeruginosa by normal and CF neutrophils. J Leukoc Biol
Jun 2008;83(6):1345-53.
[146] Painter RG, Marrero L, Lombard GA, Valentine VG, Nauseef WM,
Wang G. CFTR-mediated halide transport in phagosomes of human
neutrophils. J Leukoc Biol May 2010;87(5):933-42.
[147] Painter RG, Valentine VG, Lanson Jr NA, Leidal K, Zhang Q, Lombard
G, et al. CFTR Expression in human neutrophils and the phagolysosomal
chlorination defect in cystic fibrosis. Biochemistry (US) Aug 29
2006;45(34):10260-9.
[148] Taggart C, Coakley RJ, Greally P, Canny G, O'Neill SJ, McElvaney NG.
Increased elastase release by CF neutrophils is mediated by tumor
necrosis factor-alpha and interleukin-8. Am J Physiol Lung Cell Mol
Physiol Jan 2000;278(1):L33-41.
[149] Brennan S, Cooper D, Sly PD. Directed neutrophil migration to IL-8 is
increased in cystic fibrosis: a study of the effect of erythromycin. Thorax
Jan 2001;56(1):62-4.
[150] Alexis NE, Muhlebach MS, Peden DB, Noah TL. Attenuation of host
defense function of lung phagocytes in young cystic fibrosis patients. J
Cyst Fibros Jan 2006;5(1):17-25.
[151] Kingma PS, Dimitriou S, Wooldridge JL, Karp CL. Cftr and Neutrophil
Function: Our Children May Have the Answers. Pediatr Pulmonol 2010:
138-9.
[152] McKeon DJ, Cadwallader KA, Idris S, Cowburn AS, Pasteur MC,
Barker H, et al. Cystic fibrosis neutrophils have normal intrinsic reactive
oxygen species generation. Eur Respir J Jun 2010;35(6):1264-72.
[153] Mackarel AJ, Plant BJ, FitzGerald MX, O'Connor CM. Cystic fibrosis
sputum stimulates CD18-independent neutrophil migration across
endothelial cells. Exp Lung Res May 2005;31(4):377-90.
[154] McKeon DJ, Condliffe AM, Cowburn AS, Cadwallader KC, Farahi N,
Bilton D, et al. Prolonged survival of neutrophils from patients with
Delta F508 CFTR mutations. Thorax Jul 2008;63(7):660-1.
[155] McKeon DJ, Cadwallader KA, Condliffe AM, Bilton D, Chilvers ER.
The function and fate of neutrophils in cystic fibrosis. Thorax Dec 1
2005;60:Ii93-4.
[156] Moriceau S, Kantari C, Mocek J, Davezac N, Gabillet J, Guerrera IC,
et al. Coronin-1 is associated with neutrophil survival and is cleaved
during apoptosis: potential implication in neutrophils from cystic fibrosis
patients. J Immunol Jun 1 2009;182(11):7254-63.
[157] Moriceau S, Lenoir G, Witko-Sarsat V. In cystic fibrosis homozygotes
and heterozygotes, neutrophil apoptosis is delayed and modulated by
diamide or roscovitine: evidence for an innate neutrophil disturbance. J
Innate Immun 2010;2(3):260-6.
[158] Gaggar A, Hector A, Bratcher PE, Mall MA, Griese M, Hartl D. The role
of matrix metalloproteinases in cystic fibrosis lung disease. Eur Respir J
Sep 2011;38(3):721-7.
[159] Gaggar A, Li Y, Weathington N, Winkler M, Kong M, Jackson P, et al.
Matrix metalloprotease-9 dysregulation in lower airway secretions of
cystic fibrosis patients. Am J Physiol Lung Cell Mol Physiol Jul
2007;293(1):L96–L104.
[160] Hector A, Kormann MSD, Mack I, Latzin P, Casaulta C, Kieninger E,
et al. The Chitinase-Like Protein YKL-40 Modulates Cystic Fibrosis
Lung Disease. PLoS One Sep 20 2011;6(9).[161] Hilliard JB, Konstan MW, Davis PB. Inflammatory mediators in CF
patients. Methods Mol Med 2002;70:409-31.
[162] McAllister F, Henry A, Kreindler JL, Dubin PJ, Ulrich L, Steele C, et al.
Role of IL-17A, IL-17F, and the IL-17 receptor in regulating
growth-related oncogene-alpha and granulocyte colony-stimulating
factor in bronchial epithelium: implications for airway inflammation in
cystic fibrosis. J Immunol Jul 1 2005;175(1):404-12.
[163] Sagel SD, Kapsner RK, Osberg I. Induced sputum matrix
metalloproteinase-9 correlates with lung function and airway inflamma-
tion in children with cystic fibrosis. Pediatr Pulmonol Mar 2005;39(3):
224-32.
[164] Sagel SD, Sontag MK, Accurso FJ. Relationship Between Antimicrobial
Proteins and Airway Inflammation and Infection in Cystic Fibrosis.
Pediatr Pulmonol Apr 2009;44(4):402-9.
[165] Sagel SD, Sontag MK, Wagener JS, Kapsner RK, Osberg L, Accurso FJ.
Induced sputum inflammatory measures correlate with lung function in
children with cystic fibrosis. J Pediatr Dec 2002;141(6):811-7.
[166] Gray RD, Imrie M, Boyd AC, Innes JA, Porteous D, Greening AP.
Development of sputum calprotectin as a biomarker of cystic fibrosis
lung disease activity: Evidence from cross sectional and longitudinal
studies. Thorax Dec 2006(61):Ii34-5.
[167] Golden BE, Clohessy PA, Russell G, Fagerhol MK. Calprotectin as a
marker of inflammation in cystic fibrosis. Arch Dis Child Feb
1996;74(2):136-9.
[168] Ratjen F, Hartog CM, Paul K, Wermelt J, Braun J. Matrix
metalloproteases in BAL fluid of patients with cystic fibrosis and their
modulation by treatment with dornase alpha. Thorax Nov 2002;57(11):
930-4.
[169] Thomson E, Brennan S, Senthilmohan R, Gangell CL, Chapman AL, Sly
PD, et al. Identifying peroxidases and their oxidants in the early
pathology of cystic fibrosis. Free Radic Biol Med Nov 15 2010;49(9):
1354-60.
[170] Just J, Moog-Lutz C, Houzel-Charavel A, Canteloup S, Grimfeld A,
Witko-Sarsat V, et al. Proteinase 3 mRNA expression is induced in
monocytes but not in neutrophils of patients with cystic fibrosis. FEBS
Lett Sep 3 1999;457(3):437-40.
[171] Witko-Sarsat V, Halbwachs-Mecarelli L, Schuster A, Nusbaum P, Ueki I,
Canteloup S, et al. Proteinase 3, a potent secretagogue in airways, is present
in cystic fibrosis sputum. Am J Respir Cell Mol Apr 1999;20(4):729-36.
[172] Adib-Conquy M, Pedron T, Petit-Bertron AF, Tabary O, Corvol H,
Jacquot J, et al. Neutrophils in cystic fibrosis display a distinct gene
expression pattern. Mol Med Jan-Feb 2008;14(1-2):36-44.
[173] McNally PG, Doyle M, Taggart C, O'Neill S, Elnazir B, Greene C, et al.
Protease anti-protease balance and innate defence proteins levels in the
lungs of children with cystic fibrosis: Relationship to P. aeruginosa
colonisation status. Pediatr Pulmonol 2007:262-3.
[174] Taggart CC, Greene CM, Carroll TP, O'Neill SJ, McElvaney NG.
Elastolytic proteases: inflammation resolution and dysregulation in
chronic infective lung disease. Am J Respir Crit Care Med May 15
2005;171(10):1070-6.
[175] Moraes TJ, Plumb J, Martin R, Vachon E, Cherepanov V, Koh A, et al.
Abnormalities in the pulmonary innate immune system in cystic fibrosis.
Am J Respir Cell Mol Mar 2006;34(3):364-74.
[176] Hager M, Cowland JB, Borregaard N. Neutrophil granules in health and
disease. J Intern Med Jul 2010;268(1):25-34.
[177] Downey DG, Martin SL, Dempster M, Moore JE, Keogan MT, Starcher
B, et al. The relationship of clinical and inflammatory markers to
outcome in stable patients with cystic fibrosis. Pediatr Pulmonol Mar
2007;42(3):216-20.
[178] Reeves EP, Bergin DA, Fitzgerald S, Hayes E, Keenan J, Henry M, et al.
A novel neutrophil derived inflammatory biomarker of pulmonary
exacerbation in cystic fibrosis. J Cyst Fibros Mar 2011;11(2):100-7.
[179] Voglis S, Quinn K, Tullis E, Liu M, Henriques M, Zubrinich C, et al.
Human neutrophil peptides and phagocytic deficiency in bronchiectatic
lungs. Am J Respir Crit Care Med Jul 15 2009;180(2):159-66.
[180] Singh PK, Schaefer AL, Parsek MR, Moninger TO, Welsh MJ, Greenberg
EP. Quorum-sensing signals indicate that cystic fibrosis lungs are infected
with bacterial biofilms. Nature Oct 12 2000;407(6805):762-4.
380 D. Hartl et al. / Journal of Cystic Fibrosis 11 (2012) 363–382[181] Parks QM, Young RL, Poch KR, Malcolm KC, Vasil ML, Nick JA.
Neutrophil enhancement of Pseudomonas aeruginosa biofilm develop-
ment: human F-actin and DNA as targets for therapy. J Med Microbiol
Apr 2009;58(Pt 4):492-502.
[182] Jesaitis AJ, Franklin MJ, Berglund D, Sasaki M, Lord CI, Bleazard JB,
et al. Compromised host defense on Pseudomonas aeruginosa biofilms:
characterization of neutrophil and biofilm interactions. J Immunol Oct 15
2003;171(8):4329-39.
[183] Kharazmi A, Rechnitzer C, Schiotz PO, Jensen T, Baek L, Hoiby N.
Priming of neutrophils for enhanced oxidative burst by sputum from
cystic fibrosis patients with Pseudomonas aeruginosa infection. Eur J
Clin Invest Jun 1987;17(3):256-61.
[184] Kolpen M, Hansen CR, Bjarnsholt T, Moser C, Christensen LD, van
Gennip M, et al. Polymorphonuclear leucocytes consume oxygen in
sputum from chronic Pseudomonas aeruginosa pneumonia in cystic
fibrosis. Thorax Jan 2010;65(1):57-62.
[185] Koller B, Kappler M, Latzin P, Gaggar A, Schreiner M, Takyar S, et al.
TLR expression on neutrophils at the pulmonary site of infection:
TLR1/TLR2-mediated up-regulation of TLR5 expression in cystic
fibrosis lung disease. J Immunol Aug 15 2008;181(4):2753-63.
[186] Usher LR, Lawson RA, Geary I, Taylor CJ, Bingle CD, Taylor GW,
et al. Induction of neutrophil apoptosis by the Pseudomonas aeruginosa
exotoxin pyocyanin: a potential mechanism of persistent infection. J
Immunol Feb 15 2002;168(4):1861-8.
[187] Young RL, Malcolm KC, Kret JE, Caceres SM, Poch KR, Nichols DP,
et al. Neutrophil Extracellular Trap (NET)-Mediated Killing of Pseudomo-
nas aeruginosa: Evidence of Acquired Resistance within the CF Airway,
Independent of CFTR. PLoS One Sep 1 2011;6(9).
[188] Dacheux D, Toussaint B, Richard M, Brochier G, Croize J, Attree I.
Pseudomonas aeruginosa cystic fibrosis isolates induce rapid, type III
secretion-dependent, but ExoU-independent, oncosis of macrophages and
polymorphonuclear neutrophils. Infect Immun May 2000;68(5):2916-24.
[189] Worlitzsch D, Herberth G, Ulrich M, Doring G. Catalase, myeloperoxidase
and hydrogen peroxide in cystic fibrosis. Eur Respir J Feb 1998;11(2):
377-83 [Research Support, Non-U.S. Gov't].
[190] Reynolds WF, Sermet-Gaudelus I, Gausson V, Feuillet MN, Bonnefont
JP, Lenoir G, et al. Myeloperoxidase promoter polymorphism -463G is
associated with more severe clinical expression of cystic fibrosis
pulmonary disease. Mediators Inflamm 2006;2006(2):36735.
[191] Witko-Sarsat V, Allen RC, Paulais M, Nguyen AT, Bessou G, Lenoir G,
et al. Disturbed myeloperoxidase-dependent activity of neutrophils in
cystic fibrosis homozygotes and heterozygotes, and its correction by
amiloride. J Immunol Sep 15 1996;157(6):2728-35.
[192] van der Vliet A, Cross CE. Phagocyte oxidants and nitric oxide in cystic
fibrosis: new therapeutic targets? Curr Opin Pulm Med Nov 2000;6(6):
533-9.
[193] van der Vliet A, Eiserich JP, Marelich GP, Halliwell B, Cross CE.
Oxidative stress in cystic fibrosis: does it occur and does it matter? Adv
Pharmacol 1997;38:491-513.
[194] Tirouvanziam R. Neutrophilic inflammation as a major determinant in
the progression of cystic fibrosis. Drug News Perspect Dec 2006;19(10):
609-14.
[195] Hayes E, Pohl K, McElvaney NG, Reeves EP. The Cystic Fibrosis
Neutrophil: A Specialized Yet Potentially Defective Cell. Arch Immunol
Ther Exp Apr 2011;59(2):97–112.
[196] Downey GP. Is There a Primary Neutrophil Defect in Cf? Pediatr
Pulmonol 2011:163-4.
[197] Hector A, Jonas F, Kappler M, Feilcke M, Hartl D, Griese M. Novel
Method to Process Cystic Fibrosis Sputum for Determination of
Oxidative State. Respiration Dec 2010;80(5):393-400.
[198] Tirouvanziam R, Gernez Y, Conrad CK, Moss RB, Schrijver I, Dunn CE,
et al. Profound functional and signaling changes in viable inflammatory
neutrophils homing to cystic fibrosis airways. Proc Natl Acad Sci U S A
Mar 18 2008;105(11):4335-9.
[199] Makam M, Diaz D, Laval J, Gernez Y, Conrad CK, Dunn CE, et al.
Activation of critical, host-induced, metabolic and stress pathways marks
neutrophil entry into cystic fibrosis lungs. Proc Natl Acad Sci U S A Apr
7 2009;106(14):5779-83.[200] Hartl D, Krauss-Etschmann S, Koller B, Hordijk PL, Kuijpers TW,
Hoffmann F, et al. Infiltrated neutrophils acquire novel chemokine
receptor expression and chemokine responsiveness in chronic inflamma-
tory lung diseases. J Immunol Dec 1 2008;181(11):8053-67.
[201] Witko-Sarsat V, Sermet-Gaudelus I, Lenoir G, Descamps-Latscha B.
Inflammation and CFTR: might neutrophils be the key in cystic fibrosis?
Mediators Inflamm 1999;8(1):7–11.
[202] Brinkmann V, Reichard U, Goosmann C, Fauler B, Uhlemann Y, Weiss
DS, et al. Neutrophil extracellular traps kill bacteria. Science Mar 5
2004;303(5663):1532-5.
[203] Amulic B, Cazalet C, Hayes GL, Metzler KD, Zychlinsky A. Neutrophil
function: from mechanisms to disease. Annu Rev Immunol 2012;30:
459-89.
[204] Papayannopoulos V, Zychlinsky A. NETs: a new strategy for using old
weapons. Trends Immunol Nov 2009;30(11):513-21.
[205] Manzenreiter R, Kienberger F, Marcos V, Schilcher K, Krautgartner
WD, Obermayer A, et al. Ultrastructural characterization of cystic
fibrosis sputum using atomic force and scanning electron microscopy. J
Cyst Fibros Mar 2012;11(2):84-92.
[206] Tolker-Nielsen T, Hoiby N. Extracellular DNA and F-actin as targets in
antibiofilm cystic fibrosis therapy. Future Microbiol Aug 2009;4(6):
645-7.
[207] Ratjen F, Paul K, van Koningsbruggen S, Breitenstein S, Rietschel E,
Nikolaizik W. DNA concentrations in BAL fluid of cystic fibrosis
patients with early lung disease: influence of treatment with dornase
alpha. Pediatr Pulmonol Jan 2005;39(1):1-4.
[208] Perks B, Shute JK. DNA and actin bind and inhibit interleukin-8 function
in cystic fibrosis sputa: in vitro effects of mucolytics. Am J Respir Crit
Care Med Nov 2000;162(5):1767-72.
[209] Kirchner KK, Wagener JS, Khan TZ, Copenhaver SC, Accurso FJ.
Increased DNA levels in bronchoalveolar lavage fluid obtained from
infants with cystic fibrosis. Am J Respir Crit Care Med Nov
1996;154(5):1426-9.
[210] Young RL, Malcolm KC, Kret JE, Poch KR, Nichols D, Saavedra MT,
et al. Effective Pseudomonas Aeruginosa-Induced Neutrophil Extracel-
lular Trap Response by Normal & Cystic Fibrosis Neutrophils. Pediatr
Pulmonol 2010:281-2.
[211] McCormick A, Heesemann L, Wagener J, Marcos V, Hartl D, Loeffler J,
et al. NETs formed by human neutrophils inhibit growth of the pathogenic
mold Aspergillus fumigatus. Microbes Infect Nov 2010;12(12–13):928-36.
[212] Bonvillain RW, Painter RG, Adams DE, Viswanathan A, Lanson Jr NA,
Wang G. RNA interference against CFTR affects HL60-derived neutrophil
microbicidal function. Free Radic Biol Med Dec 15 2010;49(12):1872-80.
[213] Phennicie RT, Sullivan MJ, Singer JT, Yoder JA, Kim CH. Specific
resistance to Pseudomonas aeruginosa infection in zebrafish is mediated
by the cystic fibrosis transmembrane conductance regulator. Infect
Immun Nov 2010;78(11):4542-50.
[214] Su X, Looney MR, Su HE, Lee JW, Song Y, Matthay MA. Role of
CFTR expressed by neutrophils in modulating acute lung inflammation
and injury in mice. Inflamm Res Jul 2011;60(7):619-32.
[215] Pillay J, den Braber I, Vrisekoop N, Kwast LM, de Boer RJ, Borghans
JAM, et al. The in vivo half-life of human neutrophils Response. Blood
Jun 2 2011;117(22):6053-4.
[216] Legssyer R, Huaux F, Lebacq J, Delos M, Marbaix E, Lebecque P, et al.
Azithromycin reduces spontaneous and induced inflammation in
DeltaF508 cystic fibrosis mice. Respir Res 2006;7:134.
[217] Bruscia EM, Zhang PX, Ferreira E, Caputo C, Emerson JW, Tuck D,
et al. Macrophages directly contribute to the exaggerated inflammatory
response in cystic fibrosis transmembrane conductance regulator-/- mice.
Am J Respir Cell Mol Mar 2009;40(3):295-304.
[218] Mantovani A, Sica A. Macrophages, innate immunity and cancer:
balance, tolerance, and diversity. Curr Opin Immunol Apr 2010;22(2):
231-7.
[219] del Fresno C, Garcia-Rio F, Gomez-Pina V, Soares-Schanoski A,
Fernandez-Ruiz I, Jurado T, et al. Potent phagocytic activity with
impaired antigen presentation identifying lipopolysaccharide-tolerant
human monocytes: demonstration in isolated monocytes from cystic
fibrosis patients. J Immunol May 15 2009;182(10):6494-507.
381D. Hartl et al. / Journal of Cystic Fibrosis 11 (2012) 363–382[220] Murphy BS, Bush HM, Sundareshan V, Davis C, Hagadone J, Cory TJ,
et al. Characterization of macrophage activation states in patients with
cystic fibrosis. J Cyst Fibros Sep 2010;9(5):314-22.
[221] Krysko O, Van Zele T, Claeys S, Bachert C. Comment on "potent
phagocytic activity with impaired antigen presentation identifying
lipopolysaccharide-tolerant human monocytes: demonstration in isolated
monocytes from cystic fibrosis patients". J Immunol Oct 15 2009;183(8):
4831.
[222] Meyer M, Huaux F, Gavilanes X, van den Brule S, Lebecque P, Lo Re S,
et al. Azithromycin Reduces Exaggerated Cytokine Production by M1
Alveolar Macrophages in Cystic Fibrosis. Am J Respir Cell Mol Nov
2009;41(5):590-602.
[223] Bonfield TL, Hodges CA, Drumm ML. The epithelial cell contingency:
myeloid cells and inflammation resolution. Pediatr Pulmonol 2011;33(33):
272.
[224] Oceandy D, McMorran BJ, Smith SN, Schreiber R, Kunzelmann K,
Alton EWFW, et al. Gene complementation of airway epithelium in the
cystic fibrosis mouse is necessary and sufficient to correct the pathogen
clearance and inflammatory abnormalities. Hum Mol Genet May 1
2002;11(9):1059-67.
[225] Stoltz DA, Meyerholz DK, Pezzulo AA, Ramachandran S, Rogan MP,
Davis GJ, et al. Cystic Fibrosis Pigs Develop Lung Disease and Exhibit
Defective Bacterial Eradication at Birth. Sci Transl Med Apr 28
2010;2(29).
[226] Abdulrahman BA, Abu Khweek A, Akhter A, Caution K, Kotrange S,
Abdelaziz DHA, et al. Autophagy stimulation by rapamycin suppresses
lung inflammation and infection by Burkholderia cenocepacia in a model
of cystic fibrosis. Autophagy Nov 2011;7(11):1359-70.
[227] Deriy LV, Gomez EA, Zhang GP, Beacham DW, Hopson JA, Gallan AJ,
et al. Disease-causing Mutations in the Cystic Fibrosis Transmembrane
Conductance Regulator Determine the Functional Responses of Alveolar
Macrophages. J Biol Chem Dec 18 2009;284(51):35926-38.
[228] Di A, Brown ME, Deriy LV, Li C, Szeto FL, Chen Y, et al. CFTR
regulates phagosome acidification in macrophages and alters bactericidal
activity. Nat Cell Biol Sep 2006;8(9):933-44.
[229] Radtke AL, Anderson KL, Davis MJ, DiMagno MJ, Swanson JA,
O'Riordan MX. Listeria monocytogenes exploits cystic fibrosis trans-
membrane conductance regulator (CFTR) to escape the phagosome. Proc
Natl Acad Sci U S A Jan 25 2011;108(4):1633-8.
[230] Del Porto P, Cifani N, Guarnieri S, Di Domenico EG, Mariggio MA,
Spadaro F, et al. Dysfunctional CFTR alters the bactericidal activity of
human macrophages against Pseudomonas aeruginosa. PLoS One
2011;6(5):19970-8.
[231] Zaman MM, Gelrud A, Junaidi O, Regan MM, Warny M, Shea JC, et al.
Interleukin 8 secretion from monocytes of subjects heterozygous for the
deltaF508 cystic fibrosis transmembrane conductance regulator gene
mutation is altered. Clin Diagn Lab Immunol Sep 2004;11(5):819-24.
[232] Bruscia EM, Zhang PX, Satoh A, Caputo C, Medzhitov R, Shenoy A,
et al. Abnormal trafficking and degradation of TLR4 underlie the
elevated inflammatory response in cystic fibrosis. J Immunol Jun 15
2011;186(12):6990-8.
[233] Thomas GR, Costelloe EA, LunnDP, Stacey KJ, Delaney SJ, Passey R, et al.
G551D cystic fibrosis mice exhibit abnormal regulation of inflammation in
lungs and macrophages. J Immunol Apr 1 2000;164(7):3870-7.
[234] Andersson C, Zaman MM, Jones AB, Freedman SD. Alterations in
immune response and PPAR/LXR regulation in cystic fibrosis macro-
phages. J Cyst Fibros Jan 2008;7(1):68-78.
[235] Yoshimura K, Nakamura H, Trapnell BC, Chu CS, Dalemans W,
Pavirani A, et al. Expression of the Cystic-Fibrosis Transmembrane
Conductance Regulator Gene in Cells of Nonepithelial Origin. Nucleic
Acids Res Oct 11 1991;19(19):5417-23.
[236] Sorio C, Buffelli M, Angiari C, Ettorre M, Johansson J, Vezzalini M,
et al. Defective CFTR Expression and Function Are Detectable in Blood
Monocytes: Development of a New Blood Test for Cystic Fibrosis. PLoS
One Jul 21 2011;6(7).
[237] Haggie PM, Verkman AS. Cystic fibrosis transmembrane conductance
regulator-independent phagosomal acidification in macrophages. J Biol
Chem Oct 26 2007;282(43):31422-8.[238] Haggie PM. Does the Ph of Intracellular Organelles Differ in Cf Cells?
Pediatr Pulmonol 2009:117-8.
[239] Barriere H, Bagdany M, Bossard F, Okiyoneda T, Wojewodka G,
Gruenert D, et al. Revisiting the Role of Cftr and Counterion
Permeability in the Ph Regulation of Endolysosomes and Phagosomes.
Pediatr Pulmonol 2009:221-2.
[240] del Campo R, Martinez E, del Fresno C, Alenda R, Gomez-Pina V,
Fernandez-Ruiz I, et al. Translocated LPS might cause endotoxin
tolerance in circulating monocytes of Cystic Fibrosis patients. PLoS One
2011;6(12):29577-87.
[241] del Fresno C, Gomez-Pina V, Lores V, Soares-Schanoski A,
Fernandez-Ruiz I, Rojo B, et al. Monocytes from cystic fibrosis patients
are locked in an LPS tolerance state: down-regulation of TREM-1 as
putative underlying mechanism. PLoS One 2008;3(7):2667-75.
[242] Srivastava M, Jung S, Wilhelm J, Fink L, Buhling F, Welte T, et al. The
inflammatory versus constitutive trafficking of mononuclear phagocytes
into the alveolar space of mice is associated with drastic changes in their
gene expression profiles. J Immunol Aug 1 2005;175(3):1884-93.
[243] Vandivier RW, Henson PM, Douglas IS. Burying the dead: the impact of
failed apoptotic cell removal (efferocytosis) on chronic inflammatory
lung disease. Chest Jun 2006;129(6):1673-82.
[244] Watt AP, Courtney J, Moore J, Ennis M, Elborn JS. Neutrophil cell
death, activation and bacterial infection in cystic fibrosis. Thorax Aug
2005;60(8):659-64.
[245] Vandivier RW, Richens TR, Horstmann SA, deCathelineau AM, Ghosh
M, Reynolds SD, et al. Dysfunctional cystic fibrosis transmembrane
conductance regulator inhibits phagocytosis of apoptotic cells with
proinflammatory consequences. Am J Physiol Lung Cell Mol Physiol
Oct 2009;297(4):L677-86.
[246] Vandivier RW, Fadok VA, Ogden CA, Hoffmann PR, Brain JD, Accurso
FJ, et al. Impaired clearance of apoptotic cells from cystic fibrosis
airways. Chest Mar 2002;121(3 Suppl):89S.
[247] Vandivier RW, Fadok VA, Hoffmann PR, Bratton DL, Penvari C, Brown
KK, et al. Elastase-mediated phosphatidylserine receptor cleavage
impairs apoptotic cell clearance in cystic fibrosis and bronchiectasis. J
Clin Invest Mar 2002;109(5):661-70.
[248] Xu YQ, Tertilt C, Krause A, Quadri LEN, Crystal RG, Worgall S.
Influence of the cystic fibrosis transmembrane conductance regulator on
expression of lipid metabolism-related genes in dendritic cells. Respir
Res Apr 2009;3:10.
[249] Xu Y, Krause A,WuW, Joh J, Limberis MP, StefanW. Characterization of
Pulmonary Dendritic Cells in the Lungs of Cystic Fibrosis Mice Following
Pseudomonas Aeruginosa Infection. Pediatr Pulmonol 2009:255-6.
[250] Roghanian A, Drost EM, MacNee W, Howie SEM, Sallenave JM.
Inflammatory lung secretions inhibit dendritic cell maturation and
function via neutrophil elastase. Am J Respir Crit Care Med Dec 1
2006;174(11):1189-98.
[251] Regamey N, Tsartsali L, Hilliard TN, Fuchs O, Tan HL, Zhu J, et al.
Distinct patterns of inflammation in the airway lumen and bronchial
mucosa of children with cystic fibrosis. Thorax Feb;67(2):164–170.
[252] Schuster M, Tschernig T, Krug N, Pabst R. Lymphocytes migrate from
the blood into the bronchoalveolar lavage and lung parenchyma in the
asthma model of the brown Norway rat. Am J Respir Crit Care Med Feb
2000;161(2):558-66.
[253] Tschernig T, Boeke K, Steinhoff G, Wonigeit K, Pabst R, Westermann J.
The lung as a source and a target organ for T- and B-lymphocytes. Am J
Respir Cell Mol Oct 1997;17(4):414-21.
[254] Pabst R, Tschernig T. Lymphocytes in the Lung - an Often Neglected
Cell - Numbers, Characterization and Compartmentalization. Anat
Embryol Oct 1995;192(4):293-9.
[255] Miossec P. IL-17 and Th17 cells in human inflammatory diseases.
Microbes Infect Apr 2009;11(5):625-30.
[256] Aujla SJ, Dubin PJ, Kolls JK. Interleukin-17 in pulmonary host defense.
Exp Lung Res Dec 2007;33(10):507-18.
[257] Kuchroo V, Korn T, Bettelli E, Carrier Y, Gao W, Strom T, et al.
Interplay between pathogenic effector Th17 and regulatory T cells in
autoimmunity and tissue inflammation. Clin Exp Rheumatol Jul-Aug
2008;26(4):7145.
382 D. Hartl et al. / Journal of Cystic Fibrosis 11 (2012) 363–382[258] VeldhoenM, Hocking RJ, Atkins CJ, Locksley RM, Stockinger B. TGF beta
in the context of an inflammatory cytokine milieu supports de novo
differentiation of IL-17-producing T cells. Immunity Feb 2006;24(2):179-89.
[259] Tesmer LA, Lundy SK, Sarkar S, Fox DA. Th17 cells in human disease.
Immunol Rev Jun 2008;223:87–113.
[260] Aujla SJ, Chan YR, Zheng MQ, Fei MJ, Askew DJ, Pociask DA, et al.
IL-22 mediates mucosal host defense against Gram-negative bacterial
pneumonia. Nat Med Mar 2008;14(3):275-81.
[261] Aujla SJ, Kolls JK. IL-22: A critical mediator in mucosal host defense. J
Mol Med Immunol May 2009;87(5):451-4.
[262] Dubin PJ, Kolls JK. IL-17 in Cystic Fibrosis: More Than Just Th17
Cells. Am J Respir Crit Care Med Jul 15 2011;184(2):155-7.
[263] Dubin PJ, McAllister F, Kolls JK. Is cystic fibrosis a TH17 disease?
Inflamm Res Jun 2007;56(6):221-7.
[264] Dubin PJ, Kolls JK. IL-23 mediates inflammatory responses to mucoid
Pseudomonas aeruginosa lung infection in mice. Am J Physiol Lung Cell
Mol Physiol Feb 2007;292(2):L519-28.
[265] Dubin PJ, Martz A, Eisenstatt JR, Fox MD, Logar A, Kolls JK.
Interleukin-23-Mediated Inflammation in Pseudomonas aeruginosa
Pulmonary Infection. Infect Immun Jan 2012;80(1):398-409.
[266] Brodlie M, Lordan J, Ward C. Can cells other than Th17 lymphocytes be
important sources of IL-17 in the lungs? Thorax Dec 2011;66(12):1096-7.
[267] Brodlie M, McKean MC, Johnson GE, Anderson AE, Hilkens CMU,
Fisher AJ, et al. Raised interleukin-17 is immunolocalised to neutrophils
in cystic fibrosis lung disease. Eur Respir J Jun 2011;37(6):1378-85.
[268] Decraene A, Willems-Widyastuti A, Kasran A, De Boeck K, Bullens DM,
Dupont LJ. Elevated expression of both mRNA and protein levels of IL-17A
in sputum of stable Cystic Fibrosis patients. Respir Res Dec 2010;10:11.
[269] Tan HL, Regamey N, Brown S, Bush A, Lloyd CM, Davies JC. The
Th17 Pathway in Cystic Fibrosis Lung Disease. Am J Respir Crit Care
Med Jul 15 2011;184(2):252-8.
[270] Moss RB. Lymphocytes in cystic fibrosis lung disease: a tale of two
immunities. Clin Exp Immunol Mar 2004;135(3):358-60.
[271] Moss RB, Hsu YP, Olds L. Cytokine dysregulation in activated cystic
fibrosis (CF) peripheral lymphocytes. Clin Exp Immunol Jun
2000;120(3):518-25.
[272] Conese M. Cystic fibrosis and the innate immune system: therapeutic
implications. Endocr Metab Immune Disord Drug Targets Mar
2011;11(1):8–22.
[273] Davies JC, Johnson M, Booth C, Fidler K, Bush A, Geddes DM, et al.
Age-specific effect of the cystic fibrosis modifier gene, MBL-2. Thorax
Dec 2002;57.[274] Davies JC, Turner MW, Klein N, Grp LMCS. Impaired pulmonary status
in cystic fibrosis adults with two mutated MBL-2 alleles. Eur Respir J
Nov 2004;24(5):798-804.
[275] McDougal KE, Green DM, Vanscoy LL, Fallin MD, Grow M, Cheng S,
et al. Use of a modeling framework to evaluate the effect of a modifier
gene (MBL2) on variation in cystic fibrosis. Eur J Hum Genet Jun
2010;18(6):680-4.
[276] Taylor C, Huang B, Dorfman R, Zielenski J, Sandford A, Pare P, et al.
The effect of MBL2 gene variants on the age of first infection in Cystic
Fibrosis (CF) patients is modified by TGF beta 1 gene variants. Genet
Epidemiol Sep 2007;31(6):646-7.
[277] Weersink FJ, Frakking FN, Brouwer N, Van HM, Israels J, Nagelkerke
AF, et al. Mannose-binding lectin (MBL) in cystic fibrosis (CF). Pediatr
Pulmonol 2007:271-2.
[278] Zielenski JS, Pereira L, Culpi L, Raskin S, Tsui LC. Analysis of mannose
binding lectin (MBL) haplotyes in a large cohort of cystic fibrosis
patients. Am J Hum Genet Oct 2001;69(4):650-1.
[279] Drumm ML, Konstan MW, Schluchter MD, Handler A, Pace R, Zou F,
et al. Genetic modifiers of lung disease in cystic fibrosis. N Engl J Med
Oct 6 2005;353(14):1443-53.
[280] de Faria EJ, de Faria ICJ, Ribeiro JD, Ribeiro AF, Liessel G, Bertuzzo
CS. Association of MBL2, TGF-beta 1 and CD14 gene polymorphisms
with lung disease severity in cystic fibrosis. J Bras Pneumol Apr
2009;35(4):334-42.
[281] Gu Y, Harley IT, Henderson LB, Aronow BJ, Vietor I, Huber LA, et al.
Identification of IFRD1 as a modifier gene for cystic fibrosis lung
disease. Nature Apr 23 2009;458(7241):1039-42.
[282] Drumm ML. Modifier genes and variation in cystic fibrosis. Respir Res
2001;2(3):125-8.
[283] Wright FA, Strug LJ, Doshi VK, Commander CW, Blackman SM, Sun
L, et al. Genome-wide association and linkage identify modifier loci of
lung disease severity in cystic fibrosis at 11p13 and 20q13.2. Nat Genet
Jun 2011;43(6):539-46.
[284] Banner KH, De Jonge H, Elborn S, Growcott E, Gulbins E, Konstan M,
et al. Highlights of a workshop to discuss targeting inflammation in
cystic fibrosis. J Cyst Fibros Jan 2009;8(1):1-8.
[285] Ratjen FA. Cystic fibrosis: pathogenesis and future treatment strategies.
Respir Care May 2009;54(5):595-605.
[286] Koehler DR, Downey GP, Sweezey NB, Tanswell AK, Hu J. Lung
inflammation as a therapeutic target in cystic fibrosis. Am J Respir Cell
Mol Oct 2004;31(4):377-81.
